document type sequence filename description text html head title title head body bgcolor white style margin margin bottom font size font family time roman align right exhibit style margin margin bottom font size font family time roman align right confidential treatment requested cellectis confidential portion this document have been redacted have been separately filed with commission style margin margin bottom font size font family time roman align center research collaboration license agreement style margin margin bottom font size font family time roman align center between style margin margin bottom font size font family time roman align center pfizer style margin margin bottom font size font family time roman align center style margin margin bottom font size font family time roman align center cellectis style margin margin bottom font size font family time roman align center june style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center page valign bottom nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman definition valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman research program valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman selection pfizer target valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman selection cellectis program target valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman selection other cellectis target valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman target selection process valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman scope conduct research program valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman research plan valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman governance research program valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman alliance manager valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman conformance with valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman cellectis personnel matter valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman solicit valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman debarment certification valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman subcontractor valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman inspection valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman record valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman product development manufacturing commercialization regulatory matter valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman general valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman diligence valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman remedy breach cellectis diligence obligation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman regulatory approval valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman control commercialization activity valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman manufacturing valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman pfizer progress reporting valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman cellectis progress reporting valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman right first refusal valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman right negotiation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman license related grant right valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman grant pfizer valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content style margin margin bottom font size font family time roman align center continued table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center page valign bottom nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman grant cellectis valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman reciprocal exclusive research license disclosed know confidential information valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman retained right valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman other pfizer program valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman implied right valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman payment cellectis valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman upfront valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman research support funding valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman milestone valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman royalty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman diagnostic prognostic product valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman report payment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman maintenance record audit valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman guarantee success valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman intellectual property valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman invention valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman patent right valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman interference opposition revocation declaratory judgment action valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman infringement third party patent right valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman confidentiality valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman confidentiality valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman authorized disclosure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman public announcement publication valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman obligation connection with change control valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman representation warranty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman mutual representation warranty valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman representation warranty cellectis valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman representation warranty pfizer valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman cellectis covenant valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman mutual covenant valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content style margin margin bottom font size font family time roman align center continued table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center page valign bottom nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman representation legal counsel valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman disclaimer valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman government approval term termination valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman government approval valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman term valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman termination pfizer failure cellectis obtain shareholder approval valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman termination either party cause valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman termination pfizer convenience valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman termination insolvency cellectis valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman effect termination valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman disposition inventory product valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman survival certain obligation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman right termination research project research program pfizer upon change control cellectis valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman bankruptcy valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman limitation liability indemnification insurance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman consequential damage valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman indemnification pfizer valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman indemnification cellectis valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman procedure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman insurance valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp valign colspan style margin left text indent font size font family time roman miscellaneous valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman other cellectis target valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman assignment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman further action valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman force majeure valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman notice valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman amendment valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman waiver valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman severability valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman descriptive heading valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center table content style margin margin bottom font size font family time roman align center continued table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width width valign bottom width width valign bottom width style font family time roman font size valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp valign bottom nbsp nbsp valign bottom colspan align center page valign bottom nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman dispute resolution valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman election resolution process valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman arbitration process valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman governing valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman consent jurisdiction valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman entire agreement valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman independent contractor valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman pfizer anti bribery anti corruption practice valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman counterpart valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp style font size height height colspan height colspan height colspan style font family time roman font size valign valign bottom nbsp valign style margin left text indent font size font family time roman valign bottom nbsp valign bottom style margin left text indent font size font family time roman third party right obligation valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman exhibit style margin margin bottom font size font family time roman exhibit pfizer anti bribery anti corruption principle style margin margin bottom font size font family time roman schedule style margin margin bottom font size font family time roman schedule expected subcontractor style margin margin bottom font size font family time roman schedule research plan style margin margin bottom font size font family time roman schedule licensed patent right comprised cellectis technology style margin margin bottom font size font family time roman schedule cellectis patent right style margin margin bottom font size font family time roman schedule exception representation warranty cellectis style margin margin bottom font size font family time roman schedule exception representation warranty cellectis style margin margin bottom font size font family time roman schedule exception representation warranty cellectis style margin margin bottom font size font family time roman schedule disclosed third party agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center research collaboration license agreement style margin margin bottom text indent font size font family time roman this research collaboration license agreement agreement entered into june nbsp effective date among pfizer corporation organized existing under state delaware having place business east street york york united state pfizer cellectis corporation organized existing under france having place business croix jarry paris france cellectis pfizer cellectis each referred herein individually party collectively party style margin margin bottom text indent font size font family time roman whereas pfizer engaged research development commercialization pharmaceutical health care product developed owns proprietary right certain technology related protein engineering target validation style margin margin bottom text indent font size font family time roman whereas cellectis developed control proprietary right certain technology relating adoptive immunotherapy cell genome engineering technology style margin margin bottom text indent font size font family time roman whereas pfizer cellectis desire collaborate discover research novel active against certain designated target provide pfizer further research develop manufacture commercialize such product containing such provided herein style margin margin bottom text indent font size font family time roman therefore consideration mutual promise covenant forth below other good valuable consideration receipt sufficiency which hereby acknowledged party hereby agree follows style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign definition table style margin margin bottom text indent font size font family time roman when used this agreement following capitalized term will have meaning forth this article term defined elsewhere this agreement will given equal weight importance though forth article style margin margin bottom margin left font size font family time roman additional third party license defined section style margin margin bottom margin left font size font family time roman affiliate mean with respect person other person that control controlled under common control with such person person will regarded control another entity owns control least fifty percent nbsp equity security subject entity entitled vote election director case entity that corporation election corresponding managing authority provided however that term affiliate will include subsidiary other entity which party affiliate owns majority ordinary voting power necessary elect majority board director other managing authority restricted from electing such majority contract otherwise until such time such restriction longer effect style margin margin bottom margin left font size font family time roman agreement defined introduction this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman agreement mean utilizing cellectis technology that identified created developed targeting pfizer target style margin margin bottom margin left font size font family time roman alliance manager defined section style margin margin bottom margin left font size font family time roman annual sale mean with respect pfizer licensed product pfizer year during applicable royalty term such pfizer licensed product aggregate sale pfizer affiliate sublicensees from sale such pfizer licensed product territory during such pfizer year style margin margin bottom margin left font size font family time roman applicable mean statute rule regulation guideline other requirement that effect from time time apply party activity performed under this agreement including such statute rule regulation guideline other requirement style margin margin bottom margin left font size font family time roman applicable pfizer technology mean nbsp know controlled pfizer affiliate that invented discovered developed during term connection with pfizer affiliate activity under agreement nbsp patent right controlled pfizer affiliate date termination extent that such patent right claim know described clause nbsp above extent that such know patent right necessary further development manufacture commercialization continuation product style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman binding obligation mean with respect party nbsp oral written agreement arrangement that bind affect such party operation property including assignment license agreement loan agreement guaranty financing agreement nbsp provision such party charter bylaw other organizational document nbsp order writ injunction decree judgment court governmental authority entered against such party which such party operation property bound style margin margin bottom margin left font size font family time roman biosimilar biologic product defined section style margin margin bottom margin left font size font family time roman biosimilar notice mean copy application submitted third party under case country territory outside united state similar regulatory approval biological product which application identifies pfizer licensed product reference product with respect such product other information that describes process process used manufacture biological product style margin margin bottom margin left font size font family time roman mean biologics license application filed with united state with respect licensed product defined title code federal regulation section nbsp style margin margin bottom margin left font size font family time roman business mean other than saturday sunday that national holiday united state style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman calendar quarter mean respective period three nbsp consecutive calendar month ending march nbsp nbsp june nbsp nbsp september nbsp december nbsp long this agreement effect style margin margin bottom margin left font size font family time roman calendar year mean each successive period twelve nbsp calendar month commencing january nbsp ending december style margin margin bottom margin left font size font family time roman mean chimeric antigen receptor expressed from experimentally validated cellectis viral construct with specific molecular architecture signaling domain sequence style margin margin bottom margin left font size font family time roman mean population cell with unique experimentally validated biologic attribute expressing construct produced using cellectis technology style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman cellectis developed mean developed directed manufacture composition targeting cellectis program target style margin margin bottom margin left font size font family time roman cellectis diligence obligation defined section style margin margin bottom margin left font size font family time roman cellectis improvement style margin margin bottom margin left font size font family time roman cellectis indemnified party defined section style margin margin bottom margin left font size font family time roman cellectis insolvency event mean occurrence following nbsp case commenced against cellectis under applicable bankruptcy insolvency similar nbsp cellectis file subject institution bankruptcy reorganization liquidation receivership similar proceeding nbsp cellectis assigns substantial portion asset benefit creditor nbsp receiver custodian appointed cellectis business nbsp substantial portion cellectis business subject attachment similar process nbsp cellectis suspends threatens suspend making payment with respect class debt nbsp anything analogous event described foregoing clause nbsp through nbsp occurs under applicable jurisdiction style margin margin bottom margin left font size font family time roman cellectis know mean know comprised cellectis technology that introduced into research program cellectis pursuant applicable research plan style margin margin bottom margin left font size font family time roman cellectis compete period defined section style margin margin bottom margin left font size font family time roman cellectis patent right mean patent right comprised cellectis technology cellectis patent right existing effective date include those forth schedule attached hereto style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman cellectis product mean product incorporating targeting cellectis program target which would infringe valid claim licensed pfizer intellectual property absence license from pfizer pursuant section nbsp that claimed covered made using otherwise incorporates pfizer intellectual property developed style margin margin bottom margin left font size font family time roman cellectis program target mean plus additional cellectis program target added agreement pursuant section style margin margin bottom margin left font size font family time roman cellectis technology style margin margin bottom margin left font size font family time roman cellectis third party agreement mean agreement between cellectis third party under which cellectis obtains right cellectis licensed intellectual property style margin margin bottom margin left font size font family time roman change control mean with respect party nbsp merger reorganization consolidation such party with third party which result voting security such party outstanding immediately prior thereto ceasing represent least fifty nbsp combined voting power surviving entity immediately after such merger reorganization consolidation nbsp third party becoming beneficial owner fifty nbsp more combined voting power outstanding security such party nbsp sale other transfer third party substantially such party business asset which this agreement relates style margin margin bottom margin left font size font family time roman change order defined section style margin margin bottom margin left font size font family time roman combination product mean pfizer licensed product containing agreement more other therapeutically active ingredient style margin margin bottom margin left font size font family time roman commercialization commercialize mean activity directed marketing promoting distributing importing exporting using commercial purpose selling having sold pfizer licensed product commercialization will include activity related manufacturing development style margin margin bottom margin left font size font family time roman commercially reasonable effort mean style margin margin bottom margin left font size font family time roman confidential information party mean know other information including proprietary information material whether patentable regarding such party technology product business objective that communicated form disclosing party receiving party either prior after effective date this agreement including information disclosed pursuant confidentiality agreement whether such know other information identified confidential time disclosure term condition this agreement will deemed confidential information each party cellectis improvement will deemed confidential information cellectis pfizer improvement will deemed confidential information pfizer developed will deemed confidential information each party except that developed upon assignment thereof pfizer pursuant section nbsp will deemed confidential information solely pfizer style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman confidentiality agreement mean that certain confidentiality agreement between party dated march nbsp style margin margin bottom margin left font size font family time roman continuation product defined section style margin margin bottom margin left font size font family time roman control controlled mean with respect nbsp item information including know nbsp intellectual property right possession whether ownership interest license other than pursuant this agreement party ability grant other party access license under such item right provided herein without violating term agreement other arrangement with third party style margin margin bottom margin left font size font family time roman develop development mean discover research otherwise develop product including conducting clinical clinical clinical research drug development activity including discovery research toxicology pharmacology other similar effort test method development stability testing manufacturing process development formulation development delivery system development quality assurance quality control development statistical analysis clinical study including post approval study development diagnostic assay connection with clinical study activity directed obtaining regulatory approval including marketing pricing reimbursement approval style margin margin bottom margin left font size font family time roman developed style margin margin bottom margin left font size font family time roman development milestone defined section style margin margin bottom margin left font size font family time roman development milestone payment defined section style margin margin bottom margin left font size font family time roman diligence issue defined section style margin margin bottom margin left font size font family time roman disclosed third party agreement defined section style margin margin bottom margin left font size font family time roman disclosing party defined section style margin margin bottom margin left font size font family time roman effective date defined introduction this agreement style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman mean european medicine agency successor agency thereto style margin margin bottom margin left font size font family time roman expected subcontractor mean subcontractor contractor listed schedule that cellectis using intends effective date engage performance research plan service research program activity style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman mean united state federal food drug cosmetic amended rule regulation promulgated thereunder style margin margin bottom margin left font size font family time roman mean united state food drug administration successor agency thereto style margin margin bottom margin left font size font family time roman field mean human oncologic therapeutic diagnostic prophylactic prognostic purpose style margin margin bottom margin left font size font family time roman first commercial sale mean with respect pfizer licensed product country world first sale such pfizer licensed product under this agreement pfizer affiliate sublicensees third party such country after such pfizer licensed product been granted regulatory approval competent regulatory authority such country style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman mean full time equivalent scientific person with level equivalent degree including laboratory technician with exam recognized according european standard year consisting minimum total scientific work directly related support research program employee cellectis affiliate style margin margin bottom margin left font size font family time roman rate mean style margin margin bottom margin left font size font family time roman gaap mean united state generally accepted accounting principle consistently applied style margin margin bottom margin left font size font family time roman generic competition defined section style margin margin bottom margin left font size font family time roman governmental authority mean court agency department authority other instrumentality national state county city other political subdivision style margin margin bottom margin left font size font family time roman mean investigational drug application defined that required filed with before beginning clinical testing pfizer licensed product cellectis product applicable human subject equivalent foreign filing style margin margin bottom margin left font size font family time roman indemnified party defined section nbsp style margin margin bottom margin left font size font family time roman indemnifying party defined section style margin margin bottom margin left font size font family time roman joint developed defined section style margin margin bottom margin left font size font family time roman joint patent right defined section style margin margin bottom margin left font size font family time roman joint research committee defined section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman know mean proprietary invention discovery data information process method technique material technology result other know whether patentable style margin margin bottom margin left font size font family time roman mean statute rule regulation order judgment ordinance governmental authority style margin margin bottom margin left font size font family time roman liability defined section nbsp style margin margin bottom margin left font size font family time roman license defined section style margin margin bottom margin left font size font family time roman licensed cellectis intellectual property mean intellectual property including patent right know controlled cellectis including cellectis technology cellectis improvement cellectis interest developed pfizer make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize pfizer licensed product style margin margin bottom margin left font size font family time roman licensed pfizer intellectual property mean pfizer technology pfizer improvement pfizer interest developed cellectis make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize cellectis product style margin margin bottom margin left font size font family time roman litigation condition defined section style margin margin bottom margin left font size font family time roman mean application with seeking regulatory approval licensed product europe using centralized procedure style margin margin bottom margin left font size font family time roman major market country mean style margin margin bottom margin left font size font family time roman major market country mean major market country style margin margin bottom margin left font size font family time roman manufacturing manufacture mean activity directed making producing manufacturing processing filling finishing packaging labeling quality assurance testing release shipping storage product style margin margin bottom margin left font size font family time roman marginal royalty rate defined section style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman misuse mean cellectis confidential information know pfizer violation pfizer obligation pursuant this agreement outside scope license granted hereunder avoidance doubt misuse will include pfizer disclosure cellectis confidential information third party violation section style margin margin bottom margin left font size font family time roman necessary defined section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman sale mean style margin margin bottom margin left font size font family time roman disclosing party defined section nbsp style margin margin bottom margin left font size font family time roman notice dispute defined section style margin margin bottom margin left font size font family time roman other cellectis target mean plus additional other cellectis target added agreement pursuant section style margin margin bottom margin left font size font family time roman party party defined introduction this agreement style margin margin bottom margin left font size font family time roman patent right mean nbsp patent nbsp pending patent application including provisional application substitution continuation continuation part division renewal patent granted thereon nbsp patent addition reissue reexamination extension restoration existing future extension restoration mechanism including patent term extension supplementary protection certificate equivalent thereof nbsp inventor certificate nbsp other form government issued right substantially similar foregoing nbsp united state foreign counterpart foregoing patent right owned either party include patent right assigned such party pursuant provision this agreement style margin margin bottom margin left font size font family time roman person mean individual sole proprietorship partnership limited partnership limited liability partnership corporation limited liability company business trust joint stock company trust incorporated association joint venture similar entity organization including government political subdivision department agency government style margin margin bottom margin left font size font family time roman pfizer defined introduction this agreement style margin margin bottom margin left font size font family time roman pfizer developed style margin margin bottom margin left font size font family time roman pfizer diligence obligation defined section style margin margin bottom margin left font size font family time roman pfizer improvement style margin margin bottom margin left font size font family time roman pfizer indemnified party defined section style margin margin bottom margin left font size font family time roman pfizer know mean know comprised pfizer technology style margin margin bottom margin left font size font family time roman pfizer licensed product mean product containing agreement that claimed covered made using otherwise incorporates licensed cellectis intellectual property style margin margin bottom margin left font size font family time roman pfizer patent right mean patent right comprised pfizer technology style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman pfizer proprietary material mean biological including antibody other material controlled pfizer provided pfizer cellectis under this agreement style margin margin bottom margin left font size font family time roman pfizer quarter mean each four thirteen week period nbsp with respect united state commencing january nbsp pfizer year nbsp with respect country territory other than united state commencing december nbsp pfizer year style margin margin bottom margin left font size font family time roman pfizer target mean plus additional pfizer target added agreement pursuant section style margin margin bottom margin left font size font family time roman pfizer technology mean style margin margin bottom margin left font size font family time roman pfizer year mean month fiscal period observed pfizer nbsp commencing january nbsp with respect united state nbsp commencing december nbsp with respect country territory other than united state style margin margin bottom margin left font size font family time roman phase clinical trial mean study pfizer licensed product human subject patient with endpoint determining initial tolerance safety metabolism pharmacokinetic information clinical pharmacology such product extent defined united state successor regulation equivalent regulation other country called phase clinical trial will deemed phase clinical trial unless such study when completed allows pfizer proceed directly phase clinical trial style margin margin bottom margin left font size font family time roman phase clinical trial mean study pfizer licensed product human patient determine safe effective dose range proposed therapeutic indication extent defined united sates successor regulation equivalent regulation other country style margin margin bottom margin left font size font family time roman phase clinical trial mean study pfizer licensed product human patient with defined dose defined pfizer licensed product designed nbsp ascertain efficacy safety such pfizer licensed product intended nbsp define warning precaution adverse reaction that associated with pfizer licensed product dosage range prescribed nbsp support preparing submitting application regulatory approval competent regulatory authority country world extent defined united state successor regulation equivalent regulation other country style margin margin bottom margin left font size font family time roman mean united state public health service amended rule regulation promulgated thereunder style margin margin bottom margin left font size font family time roman price approval mean country where governmental authority authorizes reimbursement approves determines pricing pharmaceutical product receipt required make such authorization approval determination effective publication such reimbursement authorization pricing approval determination case style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman receiving party defined section style margin margin bottom margin left font size font family time roman regulatory approval mean technical medical scientific license registration authorization approval including approval blas maas supplement amendment post approval pricing third party reimbursement approval labeling approval regulatory authority necessary development manufacture commercialization pharmaceutical product regulatory jurisdiction sake clarity regulatory approval will achieved pfizer licensed product country until applicable price approval have also been obtained pfizer affiliate sublicensees distributor where applicable such pfizer licensed product such country style margin margin bottom margin left font size font family time roman regulatory approval application mean application submitted appropriate regulatory authority seeking regulatory approval style margin margin bottom margin left font size font family time roman regulatory authority mean with respect national supra national regional state local regulatory jurisdiction agency department bureau commission council other governmental entity involved granting regulatory approval such jurisdiction style margin margin bottom margin left font size font family time roman representative defined section style margin margin bottom margin left font size font family time roman research plan defined section style margin margin bottom margin left font size font family time roman research plan service defined section style margin margin bottom margin left font size font family time roman research program defined section style margin margin bottom margin left font size font family time roman research project defined section style margin margin bottom margin left font size font family time roman research term mean four nbsp year from effective date style margin margin bottom margin left font size font family time roman royalty term mean pfizer licensed product pfizer licensed product country country basis period time from first commercial sale such pfizer licensed product such country until later nbsp expiration last valid claim that would license ownership pfizer hereunder infringed sale such pfizer licensed product such country nbsp loss regulatory exclusivity pfizer licensed product such country nbsp tenth nbsp anniversary date first commercial sale such pfizer licensed product such country event later than twentieth nbsp anniversary date first commercial sale country style margin margin bottom margin left font size font family time roman sale milestone defined section style margin margin bottom margin left font size font family time roman sale milestone payment defined section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman sale threshold defined section style margin margin bottom margin left font size font family time roman mean united state security exchange commission style margin margin bottom margin left font size font family time roman servier agreement mean that certain research product development option license commercialization agreement between servier cellectis dated february nbsp style margin margin bottom margin left font size font family time roman servier target mean five other target forth servier agreement style margin margin bottom margin left font size font family time roman subcontractor defined section style margin margin bottom margin left font size font family time roman sublicensee mean person whom pfizer grant granted directly indirectly sublicense right licensed cellectis pfizer under this agreement accordance with provision this agreement style margin margin bottom margin left font size font family time roman patent right mean patent right forth schedule under heading cellectis patent portfolio licensed patent application from licensed patent application from licensed patent application from licensed from value attributed patent right corresponds total value cellectis technology style margin margin bottom margin left font size font family time roman target mean nbsp specific biological molecule that identified genbank accession number similar information amino acid nucleic acid sequence nbsp biological molecule substantially similar amino acid nucleic acid sequence that substantially same biological function molecule disclosed clause including naturally occurring mutant allelic variant molecule disclosed clause including naturally occurring variant mutant transcriptional post transcriptional isoforms alternative splice variant post translational modification variant protein processing maturation glycosylation variant nbsp truncated form including fragment thereof which have biological function substantially similar that biological molecule disclosed clause nbsp clause style margin margin bottom margin left font size font family time roman target designation date mean with respect original cellectis program target other cellectis target pfizer target effective date with respect additional pfizer target cellectis program target other cellectis target designated pursuant section nbsp such date provided section style margin margin bottom margin left font size font family time roman targeting mean when used describe relationship between molecule target that molecule nbsp bind target portion thereof nbsp designed being developed exert biological effect whole part through binding such target such portion thereof style margin margin bottom margin left font size font family time roman term defined section style margin margin bottom margin left font size font family time roman terminated pfizer licensed product defined section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman terminated target defined section style margin margin bottom margin left font size font family time roman territory mean entire world style margin margin bottom margin left font size font family time roman third party mean person other than pfizer cellectis their respective affiliate style margin margin bottom margin left font size font family time roman third party claim defined section style margin margin bottom margin left font size font family time roman trademark mean trademark trade dress design logo slogan house mark name used connection with commercialization pfizer licensed product pfizer affiliate sublicensees hereunder including registration application registration foregoing style margin margin bottom margin left font size font family time roman useful defined section style margin margin bottom margin left font size font family time roman valid claim mean with respect particular country claim issued unexpired patent right included within licensed intellectual property developed that nbsp been held permanently revoked unenforceable invalid decision court other governmental authority competent jurisdiction which decision unappealed unappealable within time allowed appeal nbsp been cancelled withdrawn abandoned disclaimed admitted invalid unenforceable through reissue disclaimer otherwise pfizer licensed product covered valid claim referenced activity pfizer sublicensees would license granted cellectis under this agreement infringe such valid claim style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman construction except where context expressly requires otherwise nbsp gender herein will deemed encompass reference either both gender singular will deemed include plural vice versa nbsp word include includes including will deemed followed phrase without limitation nbsp word will will construed have same meaning effect word shall nbsp definition reference agreement instrument other document herein will construed referring such agreement instrument other document from time time amended supplemented otherwise modified subject restriction such amendment supplement modification forth herein nbsp reference herein person will construed include person successor assigns nbsp word herein hereof hereunder word similar import will construed refer this agreement entirety particular provision hereof nbsp reference herein section exhibit will construed refer section exhibit this agreement reference this agreement include exhibit hereto nbsp word notice mean notice writing whether specifically stated will include notice consent approval other written communication contemplated under this agreement nbsp provision that require that party party committee hereunder agree consent approve like will require that such agreement consent approval specific writing whether written agreement letter approved minute otherwise style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman excluding mail instant messaging nbsp reference specific rule regulation article section other division thereof will deemed include then current amendment thereto replacement successor rule regulation thereof nbsp definition reference agreement instrument other document herein will construed referring such agreement instrument other document from time time amended supplemented otherwise modified subject restriction such amendment supplement modification forth herein nbsp term will interpreted inclusive sense commonly associated with term style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign research program table style margin margin bottom margin left font size font family time roman selection pfizer target style margin margin bottom margin left font size font family time roman pfizer target pfizer hereby designates initial pfizer target first pfizer research project style margin margin bottom margin left font size font family time roman additional pfizer target right pfizer will have right following each anniversary effective date during research term three additional pfizer target under this agreement subject availability such target forth section nbsp below style margin margin bottom margin left font size font family time roman exclusivity pfizer target subject section during term this agreement each pfizer target except forth research plan neither cellectis affiliate will nbsp grant seek grant right under cellectis technology cellectis improvement pfizer improvement licensed cellectis pursuant section nbsp developed third party with respect such pfizer target nbsp cellectis technology cellectis improvement pfizer improvement licensed cellectis pursuant section nbsp developed develop itself through with third party commercialize targeting such pfizer target style margin margin bottom margin left font size font family time roman exclusivity except extent required cellectis pursuant servier agreement until earlier nbsp completion termination research term nbsp filing cellectis cellectis program target other cellectis target together cellectis compete period neither cellectis affiliate will grant seek grant right under cellectis technology cellectis improvement pfizer improvement licensed cellectis pursuant section nbsp developed third party develop commercialize field other than academic institution solely internal academic profit research commercial research collaboration subcontractor cellectis affiliate clarity event that cellectis file product cellectis program target other cellectis target cellectis compete period will terminate such time such cellectis program target other cellectis target will remain effect other target including remaining cellectis program target other cellectis target pursuant term this section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman selection cellectis program target style margin margin bottom margin left font size font family time roman cellectis program target cellectis hereby designates initial cellectis program target first cellectis research project style margin margin bottom margin left font size font family time roman additional cellectis program target right cellectis will have right following each anniversary effective date during research term additional cellectis program target under this agreement subject availability such target forth section nbsp below style margin margin bottom margin left font size font family time roman exclusivity cellectis program target during research term until earlier nbsp completion termination research term nbsp filing cellectis cellectis program target together cellectis program target compete period neither pfizer affiliate will nbsp grant seek grant right under pfizer technology pfizer improvement cellectis improvement licensed pfizer pursuant section nbsp developed controlled pfizer third party with respect such cellectis program target field nbsp pfizer technology pfizer improvement cellectis improvement licensed pfizer pursuant section nbsp developed controlled pfizer develop itself through with third party commercialize cell expressing chimeric antigen receptor construct targeting such cellectis program target field clarity event that cellectis file product cellectis program target enters into agreement with third party related such cellectis program target other than academic institution solely internal academic profit research commercial research collaboration subcontractor cellectis program target then cellectis program target compete period will terminate such time such cellectis program target will remain effect other cellectis program target pursuant term this section style margin margin bottom margin left font size font family time roman selection other cellectis target style margin margin bottom margin left font size font family time roman other cellectis target cellectis hereby designates initial other cellectis target style margin margin bottom margin left font size font family time roman additional other cellectis target right cellectis will have right following each anniversary effective date during research term additional other cellectis target under this agreement subject availability such target forth section nbsp below style margin margin bottom margin left font size font family time roman target selection process within each anniversary effective date during research term including anniversary effective date pfizer cellectis will meet either person phone designate additional target either pfizer target cellectis program target other cellectis target style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman each such date target designation date order designation will subject limitation forth section nbsp pfizer designates pfizer target nbsp cellectis designates cellectis target either cellectis program target other cellectis target nbsp pfizer designates pfizer target nbsp cellectis designates cellectis target either cellectis program target other cellectis target nbsp pfizer designates pfizer target nbsp cellectis designates cellectis target either cellectis program target other cellectis target party hereby acknowledge agree that neither party will able designate target pfizer target cellectis program target other cellectis target applicable such target previously been designated pfizer target cellectis program target other cellectis target servier target following style font size vertical align anniversary effective date cellectis will have right obligation nominate additional target other cellectis target style margin margin bottom margin left font size font family time roman scope conduct research program under term condition forth herein cellectis pfizer will collaborate conduct discovery clinical development activity generate validate agreement pfizer target cellectis program target research program research program will conducted accordance with research plan each research project more fully provided section nbsp below each party will commercially reasonable effort perform activity assigned fulfill obligation under each research plan accordance with timeline budget forth applicable research plan addition each party will conduct activity under research plan accordance with applicable style margin margin bottom margin left font size font family time roman research plan style margin margin bottom margin left font size font family time roman adoption research plan party will adopt research plan research plan pfizer target cellectis program target research project will mean work performed pursuant such research plan initial research plan attached schedule research plan other pfizer target cellectis program target will prepared adopted within target designation date such pfizer target cellectis program target each research plan will reference this agreement will subject provision this agreement addition specific detail forth such research plan extent provision research plan conflict inconsistent with provision this agreement provision this agreement will control unless otherwise expressly stated research plan provision each research plan will independent will affect provision other research plan party unable agree research plan within specified time period specify research plan dispute regarding preparation modification research plan including approval change order will resolved pursuant procedure forth section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman responsibility each research plan will forth service obligation responsibility assigned each party under corresponding research project collectively research plan service will include following minimum term style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman payment obligation each party style margin margin bottom margin left font size font family time roman change research plan research plan amended written amendment change order such research plan proposed change order will prepared writing will subject review written approval each party each change order will forth agreed change applicable task protocol specification responsibility budget timeline other matter used this agreement research plan will deemed include change order with respect thereto each change order will reference this agreement research plan relates will subject provision this agreement extent provision change order conflict inconsistent with provision this agreement provision this agreement will control change order will incorporated herein reference form part hereof style margin margin bottom margin left font size font family time roman governance research program style margin margin bottom margin left font size font family time roman formation joint research committee cellectis pfizer will establish joint research committee oversee coordinate activity party under this agreement regard research program will also serve forum facilitate communication between party regarding research program will comprised three nbsp representative from each party appointed such party with such representative possessing appropriate expertise seniority carry research project change size from time time mutual consent member party replace more representative from time time upon written notice other party each party respectively will designate initial member within thirty nbsp after effective date will exist until expiration research term unless party otherwise agree writing style margin margin bottom margin left font size font family time roman chairperson secretary joint research committee each party will designate chairperson secretary will designated accordance with section nbsp below party change designation chairperson from time time upon written notice other party chairperson will responsible scheduling meeting preparing agenda meeting sending member notice regular meeting agenda such meeting least five nbsp business style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman before such meeting chairperson will solicit input from both party regarding matter included agenda matter either party desire have included agenda will included discussion nothing herein will construed prohibit from discussing acting matter included applicable agenda secretary will record minute meeting circulate copy meeting minute party each member promptly following meeting review comment approval member finalize approved meeting minute chairperson will member secretary need member style margin margin bottom margin left font size font family time roman meeting will meet least once each calendar quarter until been terminated accordance with section nbsp date time mutually agreed unless otherwise mutually agreed party initial meeting will held within thirty nbsp after effective date either party call special meeting fifteen nbsp written notice other party member upon such shorter notice exigent circumstance require such written notice will include agenda special meeting person meeting including special meeting will alternate between office party unless otherwise agreed upon member meeting held telephonically video conference provided however that least will held person meeting will effective only least nbsp representative each party attendance participating meeting member will have right participate vote meeting held telephone video conference addition matter issue without meeting documented written consent signed each member style margin margin bottom margin left font size font family time roman responsibility joint research committee will responsible nbsp planning supervising research development under this agreement including establishing reviewing recommending modification update research plan nbsp receiving reviewing data other information obtained either party connection with research program monitoring reporting party activity conducted pursuant research plan nbsp documenting approving initiation completion each research project nbsp evaluating requirement performance research plan nbsp such other function expressly specified hereunder agreed party style margin margin bottom margin left font size font family time roman decision member will good faith effort reach agreement matter properly brought before them related research program event that despite such good faith effort agreement particular matter reached within after first meet consider such matter such later date mutually acceptable party each such matter disputed matter then either party refer that disputed matter resolution their respective senior style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman executive such senior executive would promptly initiate discussion good faith resolve such disputed matter senior executive unable resolve disputed matter within thirty nbsp being referred them then cellectis will have final decision making authority with respect disputed matter related cellectis program target pfizer will have final decision making authority with respect other disputed matter provided that neither party will have authority obligate other party perform research plan service that substantially greater than those forth research plan attached hereto schedule style margin margin bottom margin left font size font family time roman alliance manager addition foregoing governance provision each party will appoint single individual serve that party alliance manager alliance manager role each alliance manager will facilitate relationship between party established this agreement alliance manager will attend meeting support respective chairperson such committee discharge their responsibility unless otherwise determined pfizer alliance manager will serve secretary each meeting alliance manager will voting participant such committee meeting party replace alliance manager from time time upon written notice other party style margin margin bottom margin left font size font family time roman conformance with each party will perform discharge obligation under this agreement research program conformance with nbsp professional standard practice nbsp this agreement research plan nbsp applicable without limiting generality foregoing each party will retain record relating performance this agreement research plan time period required applicable style margin margin bottom margin left font size font family time roman cellectis personnel matter cellectis acknowledges agrees that solely responsible compensation personnel assigned research plan service employer will responsible withholding national state local other applicable similar item cellectis also will responsible other employer related obligation including providing appropriate insurance coverage employee benefit making other deduction required affecting gross wage each employee cellectis personnel assigned research plan service will they deemed employee pfizer style margin margin bottom margin left font size font family time roman solicit style margin margin bottom margin left font size font family time roman cellectis employee pfizer hereby undertakes behalf itself affiliate that prior change control cellectis during period time from effective date until neither rinat pfizer oncology research unit immumo oncology oncology research unit third party acquired pfizer person acting their behalf will without prior written consent cellectis directly indirectly encourage quit attempt encourage quit director officer executive scientific research employee project leader level higher cellectis affiliate with style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman whom pfizer contact during research term provided however that pfizer engage general solicitation such through search firm newspaper other medium advertisement event that pfizer alleged have breached this section nbsp cellectis provides written notification pfizer objection such alleged breach within month such alleged breach party will reasonable effort resolve resolve such alleged breach event will breach this section nbsp deemed material breach this agreement purpose section nbsp below style margin margin bottom margin left font size font family time roman pfizer employee cellectis hereby undertakes behalf itself affiliate that prior change control pfizer during period time from effective date neither cellectis affiliate person acting their behalf will without prior written consent pfizer directly indirectly encourage quit attempt encourage quit director officer executive scientific research employee director level higher pfizer affiliate with whom cellectis contact during research term provided however that cellectis engage general solicitation such through search firm newspaper other medium advertisement event that cellectis alleged have breached this section nbsp pfizer provides written notification cellectis objection such alleged breach within month such alleged breach party will reasonable effort resolve such alleged breach event will breach this section nbsp deemed material breach this agreement purpose section nbsp below style margin margin bottom margin left font size font family time roman debarment certification neither party person employed retained perform service either party been debarred under section nbsp nbsp comparable provision foreign debarred person will future employed retained perform service either party connection with work performed behalf other party time after execution this agreement either party becomes aware that such party person employed retained perform service such party connection with work performed behalf such party process being debarred such party will notify other party immediately style margin margin bottom margin left font size font family time roman subcontractor except expected subcontractor that hereby accepted pfizer cellectis engage contractor subcontractor subcontractor perform research plan service research program activity without pfizer prior written consent provided that such decision will determined communicated timely manner consent will unreasonably withheld cellectis will responsible management permitted subcontractor engagement cellectis subcontractor compliance with this section nbsp will relieve cellectis obligation under this agreement applicable research plan agreement between cellectis permitted subcontractor pertaining research plan service will consistent with provision this agreement furthermore unless otherwise agreed pfizer writing prior time engagement subcontractor perform obligation hereunder cellectis will cause such subcontractor agree writing bound term providing pfizer right favorable pfizer than right granted pfizer this agreement style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman inspection each party authorized representative regulatory authority extent required applicable scope research plan service performed during regular business hour extent legally possible time arranged advance with other party audit inspect copy data record work product audit inspect facility relating research plan service such other party performance under this agreement applicable research plan including data record work product facility subcontractor style margin margin bottom margin left font size font family time roman record each party will prepare maintain retain complete accurate written record account note report data research plan service performance under this agreement research plan form quality reasonably acceptable both party such information will treated confidential information pfizer purpose this agreement style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign product development manufacturing commercialization regulatory matter table style margin margin bottom margin left font size font family time roman general except expressly forth article pfizer will have sole authority over control development manufacture commercialization pfizer licensed product targeting such pfizer target style margin margin bottom margin left font size font family time roman diligence style margin margin bottom margin left font size font family time roman pfizer development diligence pfizer will commercially reasonable effort develop during term avoidance doubt action taken pfizer affiliate sublicensees under this agreement will treated action taken pfizer regard satisfaction requirement this section nbsp additionally during research term pfizer affiliate sublicensees will style margin margin bottom margin left font size font family time roman initiate development within from target designation date style margin margin bottom margin left font size font family time roman develop during research term provided that there designated such development will apply remaining style margin margin bottom margin left font size font family time roman stop development during research term clarity pfizer stop development initiate development activity prior pfizer will deemed have satisfied obligation with respect this section nbsp style margin margin bottom margin left font size font family time roman cellectis development diligence cellectis will commercially reasonable effort develop least cellectis product each cellectis program target during research term avoidance doubt action style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman taken cellectis affiliate sublicensees under this agreement will treated action taken cellectis regard satisfaction requirement this section nbsp additionally cellectis affiliate sublicensees will during research term style margin margin bottom margin left font size font family time roman initiate development within from target designation date style margin margin bottom margin left font size font family time roman stop development during research term clarity cellectis stop development cellectis program target initiate development activity prior cellectis will deemed have satisfied obligation with respect this section nbsp style margin margin bottom margin left font size font family time roman commercial diligence pfizer will commercially reasonable effort commercialize where pfizer received regulatory approval such country pfizer will have other diligence obligation with respect commercialization pfizer licensed product under this agreement avoidance doubt action taken pfizer affiliate sublicensees under this agreement will treated action taken pfizer regard satisfaction requirement this section style margin margin bottom margin left font size font family time roman exception diligence obligation notwithstanding provision this agreement contrary each party will relieved from will have obligation undertake effort with respect diligence obligation under each pfizer target cellectis program target applicable pursuant section nbsp section nbsp each pfizer diligence obligation section nbsp cellectis diligence obligation event that style margin margin bottom margin left font size font family time roman pfizer cellectis receives generates safety tolerability other data reasonably indicating signaling measured pfizer safety efficacy evaluation criterion methodology that such pfizer licensed product would have unacceptable risk benefit profile otherwise reasonably suitable initiation continuation clinical trial human style margin margin bottom margin left font size font family time roman pfizer cellectis receive notice information correspondence from applicable regulatory authority applicable regulatory authority take action that reasonably indicates that such pfizer licensed product unlikely receive regulatory approval style margin margin bottom margin left font size font family time roman pfizer diligence obligation breach cellectis diligence obligation breach applicable related such pfizer target cellectis program target applicable caused negligence recklessness intentional other party style margin margin bottom margin left font size font family time roman assertion diligence obligation claim party becomes reasonably should aware fact that might form reasonable basis that other party failed meet pfizer diligence obligation cellectis diligence obligation applicable then cellectis pfizer applicable will style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman promptly notify pfizer cellectis applicable writing such potential alleged performance failure each such potential alleged performance failure diligence issue promptly upon pfizer cellectis applicable receipt notice diligence issue pursuant this section nbsp pfizer alliance manager cellectis alliance manager will meet discus specific nature such diligence issue seek identify appropriate corrective course action later than receipt such notice nbsp party have reached consensus regarding whether pfizer failed satisfy pfizer diligence obligation cellectis failed satisfy cellectis diligence obligation nbsp party respective alliance manager have agreed upon appropriate corrective course action such diligence issue then such diligence issue will escalated resolved pursuant dispute resolution provision forth section nbsp cellectis pfizer applicable fails notify pfizer cellectis applicable diligence issue pursuant this section nbsp date that cellectis pfizer applicable first discovers reasonably should have discovered such diligence issue then pfizer cellectis applicable will deemed have satisfied pfizer diligence obligation cellectis diligence obligation applicable with respect such diligence issue style margin margin bottom margin left font size font family time roman remedy breach pfizer diligence obligation pfizer materially breach pfizer diligence obligation fails remedy such breach within pfizer receipt notice such breach from cellectis then with respect pfizer target applicable pfizer target will cease pfizer target will become cellectis program target with respect pfizer target other than applicable pfizer target will longer subject exclusivity provision forth section nbsp above style margin margin bottom margin left font size font family time roman remedy breach cellectis diligence obligation cellectis materially breach cellectis diligence obligation fails remedy such breach within cellectis receipt notice such breach from pfizer then pfizer compete period with respect such cellectis program target forth section will terminate style margin margin bottom margin left font size font family time roman regulatory approval pfizer designated affiliate will file name regulatory approval application pfizer licensed product targeting such pfizer target where pfizer sole discretion determines commercially advantageous pfizer designated affiliate will have sole responsibility sole authority with respect communication with regulatory authority regarding regulatory approval application regulatory approval pfizer licensed product once granted except extent necessary fulfill obligation under section nbsp neither pfizer affiliate will have obligation seek regulatory approval pfizer licensed product style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman control commercialization activity style margin margin bottom margin left font size font family time roman general pfizer will have sole exclusive control over matter relating commercialization pfizer licensed product targeting such pfizer target style margin margin bottom margin left font size font family time roman trademark pfizer will select trademark used connection with commercialization such pfizer licensed product including goodwill associated therewith neither cellectis affiliate will seek register anywhere world trademark which confusingly similar trademark used behalf pfizer affiliate sublicensees connection with pfizer licensed product nothing this section nbsp will construed prevent cellectis from granting pfizer license right trademark trade dress design logo slogan house mark name controlled cellectis style margin margin bottom margin left font size font family time roman manufacturing pfizer will have exclusive right subject section manufacture pfizer licensed product targeting such pfizer target itself through more affiliate third party selected pfizer pfizer will have diligence obligation with respect manufacture pfizer licensed product except extent necessary fulfill pfizer diligence obligation pfizer will responsible associated cost manufacturing pfizer licensed product style margin margin bottom margin left font size font family time roman pfizer progress reporting commencing upon effective date until delivery first royalty report pursuant section nbsp pfizer will provide cellectis with annual written report pfizer activity develop commercialize pfizer licensed product targeting such pfizer target information written report provided pfizer cellectis pursuant this section nbsp will deemed pfizer confidential information subject provision article style margin margin bottom margin left font size font family time roman cellectis progress reporting commencing upon effective date until pfizer compete period cellectis will provide pfizer with annual written report cellectis activity develop commercialize product compound cellectis program target information written report provided cellectis pfizer pursuant this section nbsp will deemed cellectis confidential information subject provision article style margin margin bottom margin left font size font family time roman right first refusal style margin margin bottom margin left font size font family time roman event that cellectis proposes enter into third party agreement related development commercialization targeting cellectis program target each cellectis target product field cellectis will first provide pfizer with written notice such proposal including material term condition thereof each cellectis target product notice following receipt cellectis target product notice pfizer will have option purchase license from cellectis cellectis target product upon term condition forth cellectis target product notice event pfizer elect purchase license cellectis target product from cellectis pfizer will give written notice election cellectis style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman within such party will negotiate mutually agreeable agreement purchase license cellectis target product within provided that timeline completing agreement delayed action inaction cellectis pfizer elect purchase license cellectis target product cellectis within following expiration option right granted pfizer transfer license cellectis target product proposed transferee other transferee provided that this transfer will term condition more favorable transferee than those contained cellectis target product notice event that cellectis enter into third party agreement which cellectis target product notice relates this section nbsp will continue apply with respect cellectis product target this section nbsp will applicable potential third party agreement that cellectis proposes entering into during term related development commercialization targeting cellectis program target field style margin margin bottom margin left font size font family time roman right negotiation event that cellectis proposes enter into third party agreement related development commercialization product targeting other cellectis target cellectis will provide pfizer with written notice such intent will negotiate good faith with pfizer regarding pfizer purchase license such product targeting other cellectis target style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign license related grant right table style margin margin bottom margin left font size font family time roman grant pfizer style margin margin bottom margin left font size font family time roman exclusive license subject term condition this agreement pfizer target pfizer target basis effective target designation date such pfizer target cellectis hereby grant pfizer affiliate exclusive even cellectis except extent necessary cellectis perform obligation under research program license under licensed cellectis intellectual property excluding patent right make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize pfizer licensed product field territory with right sublicense provided section nbsp license style margin margin bottom margin left font size font family time roman patent right style margin margin bottom margin left font size font family time roman subject term condition this agreement pfizer target pfizer target basis effective target designation date such pfizer target cellectis hereby grant pfizer affiliate right engineered cellectis pursuant this agreement develop pfizer licensed product until filing each pfizer licensed product field style margin margin bottom margin left font size font family time roman exclusive license subject term condition this agreement pfizer target pfizer target basis effective upon filing style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman each individual pfizer licensed product developed under cellectis hereby grant pfizer affiliate exclusive even cellectis license under patent right make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize such pfizer licensed product field territory with right sublicense provided section nbsp sake clarity license granted pfizer cellectis herein give pfizer right style margin margin bottom margin left font size font family time roman license cellectis improvement subject term condition this agreement cellectis hereby grant pfizer affiliate exclusive worldwide sublicensable royalty free perpetual irrevocable license under cellectis improvement that were solely jointly invented employee agent independent contractor pfizer affiliate make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize product process style margin margin bottom margin left font size font family time roman right sublicense pfizer will have right grant sublicenses affiliate third party license granted pfizer under this agreement cellectis provided that nbsp pfizer will jointly severally responsible with sublicensees cellectis failure sublicensees comply with term condition this agreement nbsp each sublicense will include obligation sublicensee that consistent with term this agreement nbsp pfizer will remain responsible payment cellectis milestone payment royalty payable with respect activity sale sublicensee style margin margin bottom margin left font size font family time roman direct license affiliate pfizer time request authorize cellectis grant license directly affiliate pfizer giving written notice designating which affiliate direct license granted upon receipt such notice cellectis will enter into sign separate direct license agreement with such designated affiliate pfizer such direct license agreement will consistent with term condition this agreement except such modification required regulation country which direct license will exercised party further agree make amendment this agreement that necessary conform combined term such direct license agreement this agreement term this agreement forth effective date country where validity such direct license agreement requires prior governmental approval registration such direct license agreement will become binding between party thereto until such approval registration granted which approval registration will obtained pfizer cost making such direct license agreement including cellectis reasonable attorney under this section nbsp will borne pfizer style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman right reference cellectis hereby grant pfizer right reference that term defined data controlled cellectis affiliate nbsp that relates licensed cellectis intellectual property agreement pfizer licensed product preclinical study with respect pfizer licensed product nbsp that pfizer reasonably belief necessary useful development manufacturing commercialization agreement pfizer licensed product pursuant this agreement cellectis will provide signed statement foregoing effect requested pfizer accordance with style margin margin bottom margin left font size font family time roman technology transfer assistance pfizer cellectis will provide reasonable assistance additional cost pfizer affect timely orderly transfer pfizer know included licensed cellectis intellectual property necessary pfizer performing responsibility under research plan development manufacturing commercialization pfizer licensed product pursuant license style margin margin bottom margin left font size font family time roman grant cellectis style margin margin bottom margin left font size font family time roman research license subject term condition this agreement during research term with respect each pfizer target pfizer hereby grant cellectis exclusive worldwide royalty free license with right grant sublicenses under pfizer technology perform activity assigned cellectis under applicable research plan style margin margin bottom margin left font size font family time roman exclusive license subject term condition this agreement pfizer hereby grant cellectis affiliate exclusive worldwide royalty free perpetual irrevocable license under licensed pfizer intellectual property controlled pfizer solely make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize cellectis product targeting cellectis program target cellectis will have right grant sublicenses foregoing license third party collaborator following cellectis compete period only cellectis entered into written agreement with such third party collaborator nbsp obtaining covenant nbsp granting pfizer exclusive worldwide royalty free perpetual irrevocable license under improvement cellectis technology developed framework collaboration between cellectis such third party that controlled such third party style margin margin bottom margin left font size font family time roman license pfizer improvement subject term condition this agreement pfizer hereby grant cellectis affiliate exclusive worldwide sublicensable royalty free perpetual irrevocable license under pfizer improvement that were solely jointly invented employee agent independent contractor cellectis affiliate make have made have used sell have sold offer sale have offered sale import have imported otherwise exploit commercialize product process style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman technology transfer assistance cellectis pfizer will provide reasonable assistance additional cost cellectis affect timely orderly transfer cellectis know included pfizer technology pfizer improvement developed solely owned pfizer developed applicable necessary cellectis performing responsibility under research plan development manufacturing commercialization cellectis product targeting cellectis program target pursuant license under section above style margin margin bottom margin left font size font family time roman reciprocal exclusive research license disclosed know confidential information without limiting other license granted either party under this agreement subject term section style margin margin bottom margin left font size font family time roman cellectis hereby grant pfizer affiliate exclusive irrevocable perpetual transferable royalty free fully paid worldwide license cellectis know included licensed cellectis intellectual property cellectis confidential information disclosed pfizer during term this agreement solely internal research purpose style margin margin bottom margin left font size font family time roman pfizer hereby grant cellectis affiliate exclusive irrevocable perpetual transferable royalty free fully paid worldwide license pfizer know pfizer confidential information other than information regarding identity pfizer reason selecting pfizer target additional pfizer target which will only disclosed cellectis representative necessary comply with term this agreement disclosed cellectis during term this agreement solely internal research purpose style margin margin bottom margin left font size font family time roman notwithstanding foregoing neither pfizer cellectis will have right under this section nbsp make physical material supplied other party research program other than research program style margin margin bottom margin left font size font family time roman retained right avoidance doubt except expressly provided regard license contained this article nbsp provision section nbsp each party will retain ownership pfizer technology cellectis technology applicable style margin margin bottom margin left font size font family time roman other pfizer program cellectis understands acknowledges that pfizer have present future initiative opportunity including initiative opportunity with affiliate third party involving similar product program technology process that similar that compete with product program technology process covered this agreement cellectis acknowledges agrees that nothing this agreement will construed representation warranty style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman covenant inference that pfizer will itself develop manufacture commercialize enter into business relationship with more affiliate third party develop manufacture commercialize product program technology process that similar that compete with product program technology process covered this agreement notwithstanding foregoing pfizer affiliate other than pursuant this agreement themselves develop manufacture commercialize enter into business relationship with more affiliate third party develop manufacture commercialize cell expressing chimeric antigen receptor construct other than with respect particular pfizer target field then exclusive license granted pfizer under this agreement with respect pfizer licensed product targeting such pfizer target will automatically converted into exclusive license cellectis exclusivity obligation under section will apply with respect such pfizer target style margin margin bottom margin left font size font family time roman implied right except expressly provided this agreement neither party will deemed estoppel implication otherwise have granted other party license other right with respect intellectual property such party style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign payment cellectis table style margin margin bottom margin left font size font family time roman upfront within effective date unless this agreement terminated pfizer pursuant section nbsp below pfizer will cellectis concurrent with purchase pfizer cellectis security pursuant subscription agreement creditable refundable amount eighty million dollar style margin margin bottom margin left font size font family time roman research support funding style margin margin bottom margin left font size font family time roman research program payment each party will other party cost expense forth each research plan provided that pfizer will bear cost associated with research plan service performed cellectis related pfizer target forth research plan rate during research term pfizer will provide pfizer ftes research plan service related cellectis program target utilizing pfizer infrastructure technology forth research plan subject foregoing shall determine specific number ftes that shall perform research plan service cellectis from time time notwithstanding foregoing pfizer shall only obligated reimburse cellectis number ftes actually incurred reported pursuant section nbsp performance research plan service style margin margin bottom margin left font size font family time roman other expense except expressly forth section nbsp each party will solely responsible cost expense incurs performing obligation under research program pfizer will funding capital equipment required pfizer site cellectis will funding capital equipment required cellectis site pfizer will funding capital equipment required cellectis site style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman that will later time transferred pfizer cellectis will funding capital equipment required pfizer site that will later time transferred cellectis style margin margin bottom margin left font size font family time roman report reimbursement payment within thirty nbsp after each calendar quarter research term cellectis will provide pfizer with quarterly report containing detailed account activity performed together with invoice amount payable under section nbsp with respect such calendar quarter each report must accompanied certificate executed duly appointed officer cellectis confirming actual total number hour supplied cellectis during such calendar quarter identity number hour performed each individual performing research plan service during such calendar quarter payment shall within after pfizer receives such invoice from cellectis style margin margin bottom margin left font size font family time roman audit right during research term period cellectis shall keep maintain accurate complete record showing time devoted activity performed each performing cellectis obligation under research program upon prior written notice from pfizer cellectis shall permit independent certified public accounting firm nationally recognized standing selected pfizer reasonably acceptable cellectis examine pfizer sole expense relevant book record cellectis reasonably necessary verify accuracy invoice submitted pfizer under section nbsp number ftes applied performance cellectis obligation under research program examination pfizer under this section nbsp shall occur more than shall limited pertinent book record before date request such examination shall conducted during cellectis normal business hour cellectis facility where such book record normally kept cellectis require accounting firm sign reasonable customary disclosure agreement accounting firm shall provide both cellectis pfizer written report disclosing whether invoice submitted cellectis correct incorrect specific detail concerning discrepancy accounting firm determines number ftes actually utilized cellectis than number funded pfizer during period covered audit cellectis shall pfizer sole discretion either nbsp refund excess payment pfizer within receipt auditor report concluding nbsp immediately offset such excess payment against outstanding future amount payable pfizer cellectis under this agreement until pfizer received full credit such overpayment additionally amount refunded exceeds amount that properly payable cellectis shall reimburse pfizer cost audit style margin margin bottom margin left font size font family time roman milestone style margin margin bottom margin left font size font family time roman development milestone pfizer will cellectis amount forth below within receipt cellectis invoice following first occurrence style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman each event each development milestone described below each pfizer licensed product each pfizer target each such amount development milestone payment payable only once with respect each pfizer licensed product targeting pfizer target avoidance doubt development milestone payment paid agreement pfizer licensed product targeting pfizer target development commercialization such agreement pfizer licensed product terminated such agreement pfizer licensed product replaced with another agreement pfizer licensed product targeting same pfizer target such development milestone payment will owed pfizer such agreement pfizer licensed product later achieves same development milestone style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman development milestone valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid development milestone nbsp payment valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp table style margin margin bottom margin left font size font family time roman development milestone described above occurs before previous development milestone occurs then development milestone that been paid achievement previous development milestone shall become upon achievement subsequent development milestone payable together with payment upon achievement such subsequent development milestone clarity achievement development milestone related will result payment other development milestone related style margin margin bottom margin left font size font family time roman sale milestone pfizer will cellectis following time payment each sale milestone payment within last pfizer year when aggregate annual sale pfizer licensed product pfizer year first reach respective threshold sale threshold indicated below each sale milestone provided that such sale threshold with respect pfizer licensed product must reached within following first commercial sale such pfizer licensed product territory style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman total annual sale valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid sale nbsp milestone payment valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman royalty with respect each pfizer licensed product subject provision section nbsp pfizer will cellectis royalty amount applicable rate marginal royalty rate forth below annual sale pfizer licensed product targeting such pfizer target during royalty term style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size align center width valign bottom width style font family time roman font size valign bottom nowrap style border bottom solid width font size font family time roman annual sale valign bottom nbsp nbsp valign bottom colspan align center style border bottom solid marginal nbsp royalty rate nbsp nbsp nbsp annual nbsp nbsp sale valign bottom nbsp bgcolor cceeff style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp style font family time roman font size valign style margin left text indent font size font family time roman valign bottom nbsp nbsp valign bottom nbsp valign bottom align right nowrap valign bottom nbsp table style margin margin bottom margin left font size font family time roman marginal royalty rate application each marginal royalty rate forth table above will apply only that portion annual sale given pfizer licensed product territory during given pfizer year that fall within indicated range style margin margin bottom margin left font size font family time roman royalty adjustment following adjustment will made pfizer licensed product pfizer licensed product country country basis royalty payable pursuant this section style margin margin bottom margin left font size font family time roman generic competition royalty payable following establishment generic competition with respect sale third party product that biosimilar biologic product such pfizer licensed product such country will payable otherwise applicable rate prior application this section nbsp generic competition mean with respect given calendar year with respect pfizer licensed product country that during such calendar year nbsp more third party have received regulatory approval sell such country biosimilar biologic product such biosimilar biologic product will commercially available such country such biosimilar biologic product will have aggregate product will biosimilar biologic product with respect pfizer licensed product such product nbsp been licensed biosimilar interchangeable product pursuant section nbsp public health service amended subsequent superseding statute regulation nbsp been licensed similar biological medicinal product pursuant directive amended subsequent superseding statute regulation nbsp otherwise achieved analogous regulatory approval from another applicable regulatory authority style margin margin bottom margin left font size font family time roman third party patent after effective date necessary useful pfizer license more patent right from more third party order develop manufacture commercialize pfizer licensed product whether directly through pfizer affiliate sublicensee then pfizer sole discretion negotiate obtain license under such patent style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman right each such third party license referred herein additional third party license royalty otherwise payable cellectis under this agreement with respect sale pfizer licensed product pfizer affiliate sublicensees will reduced amount payable third party pursuant additional third party license such reduction continue until such amount have been expended provided that event will total royalty payable cellectis pfizer licensed product than event will royalty payable cellectis pfizer licensed product reduced below each case other than case cellectis breach representation warranty covenant hereunder purpose this section nbsp nbsp necessary mean that without license third party patent right development manufacture commercialization pfizer licensed product form such pfizer licensed product exists time that additional third party license executed would pfizer opinion infringe such third party patent right nbsp useful mean that pfizer determined discretion that such third party patent right would enhance commercial potential such pfizer licensed product avoidance doubt party agree acknowledge that this section nbsp will apply with respect royalty payable pfizer third party under agreement existence effective date neither party will intentionally negotiate with third party exclusive license that excludes sublicense right other party event such third party right necessary determined negotiating party develop commercialize licensed pfizer product cellectis product connection with research program field style margin margin bottom margin left font size font family time roman cellectis third party agreement cellectis will solely responsible obligation including royalty obligation that owing become owing with respect cellectis third party agreement that effect effective date that cellectis affiliate enters into during term this agreement style margin margin bottom margin left font size font family time roman fully paid royalty free license after expiration royalty term pfizer licensed product country territory further royalty will payable respect sale such pfizer licensed product such country thereafter license with respect such pfizer licensed product such country will fully paid perpetual exclusive irrevocable royalty free license style margin margin bottom margin left font size font family time roman diagnostic prognostic product event will milestone sale royalty payment become owing pursuant section above with respect pfizer licensed product developed commercialized diagnostic prognostic purpose style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman report payment style margin margin bottom margin left font size font family time roman cumulative royalty obligation royalty under section nbsp will imposed only once with respect single unit pfizer licensed product regardless many valid claim patent right included within licensed cellectis intellectual property would this agreement infringed sale such pfizer licensed product country which such pfizer licensed product used sold style margin margin bottom margin left font size font family time roman royalty statement payment within after each pfizer quarter pfizer will deliver cellectis report setting forth such pfizer quarter following information pfizer licensed product pfizer licensed product basis nbsp sale each pfizer licensed product nbsp basis adjustment royalty payable sale each pfizer licensed product nbsp royalty hereunder sale each pfizer licensed product such report will pfizer licensed product before first commercial sale such pfizer licensed product territory total royalty sale pfizer licensed product during such pfizer quarter will remitted time such report delivered cellectis style margin margin bottom margin left font size font family time roman withholding understood agreed between party that payment made under this agreement exclusive value added similar which will added thereon applicable where properly added payment made under this agreement party making payment will amount only receipt valid invoice issued accordance with regulation country which chargeable addition event payment made pfizer pursuant this agreement become subject withholding under jurisdiction pfizer will deduct withhold amount such account cellectis extent required such amount payable cellectis will reduced amount deducted withheld pfizer will amount such proper governmental authority timely manner promptly transmit cellectis official certificate other evidence such obligation together with proof payment from relevant governmental authority amount deducted withheld sufficient enable cellectis claim such payment such withholding required under applicable paid withheld will expense borne solely cellectis pfizer will provide cellectis with reasonable assistance enable cellectis recover such permitted style margin margin bottom margin left font size font family time roman currency amount payable calculation hereunder will united state dollar applicable sale royalty deduction will converted into united state dollar accordance with pfizer customary usual conversion procedure consistently applied style margin margin bottom margin left font size font family time roman method payment except permitted pursuant section nbsp each payment hereunder will made electronic transfer immediately available fund either bank wire transfer automated clearing house style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman mechanism other mean electronic fund transfer pfizer election such bank account cellectis will designate writing pfizer least forty five nbsp before payment style margin margin bottom margin left font size font family time roman additional provision relating payment cellectis acknowledges agrees that nothing this agreement including schedule exhibit hereto will construed representing estimate projection either nbsp number pfizer licensed product that will successfully developed commercialized nbsp anticipated sale actual value pfizer licensed product pfizer make representation warranty either express implied that will able successfully develop commercialize product commercialized that will achieve particular sale level such product provided that foregoing will limit pfizer obligation under this agreement style margin margin bottom margin left font size font family time roman maintenance record audit style margin margin bottom margin left font size font family time roman record keeping pfizer will keep cause affiliate sublicensees keep accurate book account record connection with sale pfizer licensed product sufficient detail permit accurate determination figure necessary verification royalty paid hereunder pfizer will maintain cause affiliate sublicensees maintain such record period least after calendar year which they were generated style margin margin bottom margin left font size font family time roman audit upon thirty nbsp prior written notice from cellectis pfizer will permit independent certified public accounting firm internationally recognized standing selected cellectis reasonably acceptable pfizer examine cellectis sole expense relevant book record pfizer during period covered such examination reasonably necessary verify accuracy report submitted pfizer accordance with section nbsp payment royalty hereunder examination cellectis under this section nbsp will occur more than will limited pertinent book record calendar year ending more than before date request accounting firm will provided access such book record pfizer affiliate facility where such book record kept such examination will conducted during pfizer normal business hour pfizer require accounting firm sign reasonable customary disclosure agreement before providing accounting firm access pfizer facility record upon completion audit accounting firm will provide both pfizer cellectis written report disclosing whether report submitted pfizer correct incorrect whether royalty paid correct incorrect each case specific detail concerning discrepancy other information will provided cellectis style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman underpayment overpayment such accounting firm concludes that additional royalty were cellectis pfizer will cellectis additional royalty within thirty nbsp date pfizer receives such accountant written report concluding such underpayment exceeds royalty that were paid cellectis pfizer also will reimburse cellectis reasonable charge such accountant conducting audit such accounting firm concludes that pfizer overpaid royalty cellectis cellectis will repay such amount pfizer full within thirty nbsp receipt such accountant report pfizer option pfizer will entitled offset such overpayment against outstanding future amount payable cellectis hereunder until pfizer received full credit such overpayment style margin margin bottom margin left font size font family time roman confidentiality financial information pfizer which subject review under this section nbsp will deemed pfizer confidential information subject provision article hereof cellectis will disclose such confidential information third party such confidential information purpose other than verifying payment made pfizer cellectis hereunder style margin margin bottom margin left font size font family time roman cost cellectis shall full cost audit unless discrepancy cellectis detriment greater than amount such calendar year which case pfizer shall reasonable cost charged such accountant such inspection style margin margin bottom margin left font size font family time roman guarantee success pfizer cellectis acknowledge agree that payment cellectis pursuant section nbsp section nbsp section nbsp nbsp have been included this agreement basis that they only payable otherwise relevant pfizer licensed product successfully developed commercialized applicable nbsp solely intended allocate amount that achieved upon successful development commercialization pfizer licensed product between pfizer will receive pfizer licensed product sale revenue cellectis nbsp intended used will used measure damage this agreement terminated reason including pursuant pfizer right terminate convenience before such success achieved such amount become nbsp will only triggered will only relevant provided accordance with term condition such provision pfizer cellectis further acknowledge agree that nothing this agreement will construed representing estimate projection nbsp successful development commercialization pfizer licensed product under this agreement nbsp number pfizer licensed product that will successfully developed commercialized under this agreement nbsp anticipated sale actual value pfizer licensed product that successfully developed commercialized under this agreement nbsp damage that payable this agreement terminated reason pfizer make representation warranty covenant either express implied that nbsp will successfully develop manufacture commercialize continue develop manufacture commercialize pfizer licensed product country nbsp commercialized that pfizer licensed product will achieve particular sale level whether individual country style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman cumulatively throughout territory nbsp pfizer will devote cause devoted level diligence resource developing commercializing pfizer licensed product country territory general other than expressly required under section nbsp style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign intellectual property table style margin margin bottom margin left font size font family time roman invention style margin margin bottom margin left font size font family time roman ownership determination inventorship under this agreement will made accordance with united state style margin margin bottom margin left font size font family time roman pfizer improvement pfizer will style margin margin bottom margin left font size font family time roman cellectis improvement cellectis will style margin margin bottom margin left font size font family time roman developed except provided section nbsp style margin margin bottom margin left font size font family time roman assignment pfizer developed style margin margin bottom margin left font size font family time roman assignment cellectis developed style margin margin bottom margin left font size font family time roman implementation each party will assign hereby assign other party such patent right know other intellectual property right necessary achieve ownership provided this section nbsp each assigning party will execute deliver document instrument reasonably requested other party evidence record such assignment file perfect enforce assigned right each assigning party will make relevant employee agent independent contractor their assignment signature such document instrument reasonably available other party assistance accordance with this section nbsp charge style margin margin bottom margin left font size font family time roman disclosure each party will promptly event than before filing initial patent right disclosing such intellectual property disclose other party developed cellectis improvement pfizer improvement including invention disclosure other similar document submitted such party affiliate employee agent independent contractor describing such developed cellectis improvement pfizer improvement proposed inventorship patent right intended filed other party will promptly raise issue regarding inventorship inventorship issue raised more than after notice filing initial patent right content thereof subsequent filing patent claim patent right directed substantially different invention will affect ownership patent right determined accordance with initial inventorship determination style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman patent right style margin margin bottom margin left font size font family time roman filing prosecution maintenance patent right style margin margin bottom margin left font size font family time roman cooperation without limiting other right obligation party under this agreement party will cooperate with respect timing scope filing patent application patent claim relating cellectis improvement pfizer improvement developed preserve enhance patent protection agreement including manufacture thereof ownership right patent right included cellectis improvement developed substantially impeding would substantially impede pfizer prosecution developed assigned pfizer pursuant section nbsp cellectis prosecution cellectis developed assigned cellectis pursuant party will negotiate good faith amendment ownership such patent right included cellectis improvement developed while preserving each party substantially same right including milestone payment royalty payment afforded this agreement style margin margin bottom margin left font size font family time roman pfizer patent right pfizer expense will have sole right obligation prepare file prosecute maintain throughout world patent right that solely owns including pfizer patent right patent right comprised pfizer improvement developed extent assigned pfizer pursuant section nbsp pfizer will keep cellectis informed regarding status patent right comprised such developed cellectis reasonable request extent pfizer wish file prosecute maintain such patent right pfizer will provide cellectis with thirty nbsp prior written notice such effect which event cellectis elect continue filing prosecution maintenance such patent right pfizer upon cellectis written request received within such thirty nbsp period will execute such document perform such cellectis expense reasonably necessary permit cellectis file prosecute maintain such patent right such patent right that prosecuted maintained cellectis pursuant this section nbsp will continue owned pfizer nbsp subject party other right obligation under this agreement licensed pfizer more third party style margin margin bottom margin left font size font family time roman cellectis patent right cellectis expense will have sole right obligation prepare file prosecute maintain throughout world patent right included licensed intellectual property that solely owns licensed from third party including cellectis patent right patent right comprised cellectis improvement cellectis will disclose pfizer confidential information patent right that file connection with prosecution such patent right without pfizer prior written consent cellectis will notify pfizer promptly upon filing otherwise style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman obtaining right patent right after effective date that cover cover development manufacture commercialization pfizer licensed product absence such prompt notification such patent right will excluded from valid claim definition cellectis will keep pfizer informed regarding each patent right included licensed intellectual property that cellectis third party licensor prosecuting will consider good faith recommendation made pfizer regard filing prosecution maintenance such patent right extent cellectis wish file prosecute maintain such patent right other than such patent right owned owned third party licensor cellectis will provide pfizer with thirty nbsp prior written notice such effect which event pfizer elect continue filing prosecution maintenance such patent right cellectis upon pfizer written request received within such thirty nbsp period will execute such document perform such pfizer expense reasonably necessary permit pfizer file prosecute maintain discretion such patent right such patent right that prosecuted maintained pfizer pursuant this section nbsp will continue owned cellectis will excluded from valid claim definition addition exclusive license granted pfizer under section nbsp cellectis will hereby grant pfizer subject existing third party right exclusive sublicensable perpetual irrevocable royalty free fully paid worldwide license practice exploit such patent right purpose cellectis will decline participate filing prosecution maintenance patent right under cellectis third party agreement that included licensed intellectual property without pfizer prior written consent style margin margin bottom margin left font size font family time roman joint patent right event party conceive generate joint developed other than joint developed that constitutes developed assigned pfizer pursuant section nbsp cellectis developed assigned cellectis pursuant section nbsp party will promptly meet discus determine based mutual consent whether seek patent protection thereon neither party will file patent right covering claiming such joint developed joint patent right pfizer will have first right file control prosecution patent right covering claiming joint developed used development manufacture composition targeting such pfizer target accordance with section nbsp avoidance doubt prosecution used this section nbsp includes opposition nullity revocation action post grant review other patent office proceeding involving referenced patent right style margin margin bottom margin left font size font family time roman liability extent that party obtaining prosecuting maintaining patent right included licensed intellectual property developed including developed otherwise exercising right under this section nbsp such party affiliate employee agent representative will liable other party respect omission default neglect part such party affiliate employee agent representative connection with such activity undertaken good faith style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman extension decision file patent term extension particular thereof including which patent extend will made with goal obtaining optimal patent term scope protection pfizer licensed product pfizer will have sole right obligation apply obtain patent term extension related extension right including supplementary protection certificate similar right patent relating pfizer licensed product including choice which patent extend provided that will consult with cellectis before applying obtaining such extension right patent included licensed cellectis intellectual property party will provide reasonable assistance each other connection with obtaining such extension patent included licensed cellectis intellectual property extent reasonably legally required order obtain such extension particular country each party will make available other copy necessary documentation enable such other party same purpose obtaining extension such country style margin margin bottom margin left font size font family time roman joint research agreement this agreement will understood joint research agreement under entered into purpose researching identifying developing agreement pfizer licensed product style margin margin bottom margin left font size font family time roman recording party deems necessary desirable register record this agreement evidence this agreement with patent office other appropriate government authority more jurisdiction territory then party will agree proposed evidence such recording party will comply with term section nbsp respect such filing each party will execute deliver other party document necessary desirable complete such registration recordation accordance with term section style margin margin bottom margin left font size font family time roman enforcement patent right style margin margin bottom margin left font size font family time roman notice either pfizer cellectis becomes aware infringement that affect competition either party within field anywhere world issued patent right within licensed intellectual property developed such party will promptly notify other party writing that effect style margin margin bottom margin left font size font family time roman infringement certain patent right style margin margin bottom margin left font size font family time roman subject term condition applicable cellectis third party agreement infringement patent right included licensed intellectual property third party arises from development manufacture style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman commercialization product that compete with pfizer licensed product targeting such pfizer target pfizer will have first right obligation take action obtain discontinuance infringement bring suit against third party infringer such patent right within nbsp month from date notice join cellectis party plaintiff each following circumstance nbsp where pfizer licensed product with which third party infringement will compete been subject cellectis product product another cellectis licensee begun completed nbsp where such patent right directed exclusively pfizer target pfizer licensed product targeting such pfizer target other circumstance pfizer with prior written consent cellectis unreasonably withheld have right take action against such third party infringer style margin margin bottom margin left font size font family time roman pfizer will bear expense suit brought claiming infringement such patent right cellectis will cooperate with pfizer such suit will have right consult with pfizer participate represented independent counsel such litigation expense pfizer will incur liability cellectis consequence such litigation unfavorable decision resulting therefrom including decision holding such patent right invalid unenforceable pfizer will without cellectis prior written consent enter into settlement consent decree that requires payment admits imparts other liability cellectis admits invalidity unenforceability such patent right style margin margin bottom margin left font size font family time roman pfizer obtained discontinuance infringement filed suit against such third party infringer within nbsp month period forth subsection nbsp above then cellectis will have right obligation bring suit against such third party infringer cellectis sole expense provided however that cellectis will only have foregoing right pfizer would required applicable otherwise join such suit party such suit would involve patent right covering then existing agreement pfizer licensed product pfizer will have obligation cooperate with cellectis such litigation provided that pfizer sole discretion elect consult with cellectis participate represented independent counsel such litigation expense cellectis will incur liability pfizer consequence such litigation unfavorable decision resulting therefrom including decision holding such cellectis patent right joint patent right invalid unenforceable cellectis will style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman without pfizer prior written consent enter into settlement consent decree that requires payment admits imparts other liability pfizer admits invalidity unenforceability such patent right style margin margin bottom margin left font size font family time roman enforcing party will keep other party reasonably informed material development connection with such suit subject term condition applicable cellectis third party agreement recovery obtained either party result proceeding against such third party infringer will allocated follows style margin margin bottom margin left font size font family time roman such recovery will first used reimburse each party pocket litigation cost connection with such litigation paid that party style margin margin bottom margin left font size font family time roman with respect remaining portion such recovery pfizer enforcing party cellectis will receive amount equal royalty that would payable pursuant section nbsp amount sale relevant pfizer licensed product country where such infringement occurred equal such remaining portion such recovery pfizer will receive remaining portion such recovery style margin margin bottom margin left font size font family time roman with respect remaining portion such recovery cellectis enforcing party cellectis will receive remaining portion such recovery except extent such recovery calculated based lost sale pfizer which case allocation such remaining portion will made provided section nbsp style margin margin bottom margin left font size font family time roman other infringement joint patent right with respect notice third party infringer joint patent right other than case joint patent right subject section nbsp party will meet soon reasonably practicable discus such infringement determine appropriate course action party respective right responsibility with respect enforcement thereof style margin margin bottom margin left font size font family time roman biosimilar notice style margin margin bottom margin left font size font family time roman upon pfizer request time after completion first phase clinical trial pfizer licensed product cellectis will reasonable effort assist cooperate with pfizer establishing strategy responding request information from regulatory authority third party requestors preparing submission responsive biosimilar notice received pfizer provided that pfizer will make final decision with respect such strategy such response style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman biosimilar notice pfizer will comply with applicable provision amendment successor statute thereto similar statutory regulatory requirement enacted future regarding biologic product united state similar statutory regulatory requirement country other regulatory jurisdiction each case with respect biosimilar notice received pfizer from third party regarding pfizer licensed product that being commercialized applicable jurisdiction exchange information between third party pfizer pursuant such requirement provided that prior submission information pfizer third party cellectis will have right review patent information included such proposed submission solely with respect patent right controlled cellectis make suggestion change such patent information that cellectis reasonably belief necessary provided further that pfizer will determine final content such submission case pfizer licensed product approved united state under case country territory other than united state similar extent permitted applicable pfizer sponsor application pfizer licensed product will reference product sponsor under pfizer will give written notice cellectis receipt biosimilar notice received pfizer with respect pfizer licensed product pfizer will consult with cellectis with respect selection patent right submitted pursuant similar country territory outside united state provided that pfizer will have final such selection patent right cellectis agrees bound confidentiality provision order establish standing connection with action brought pfizer under this section nbsp cellectis upon pfizer request will reasonably cooperate with pfizer such action including timely commencing joining action brought pfizer under this section nbsp solely extent patent right controlled cellectis involved such action party right responsibility regarding action will determined accordance with section nbsp style margin margin bottom margin left font size font family time roman interference opposition revocation declaratory judgment action party mutually determine that based upon review third party patent patent application other intellectual property right desirable connection with agreement pfizer licensed product provoke institute interference opposition revocation post grant review other patent office proceeding declaratory judgment action with respect thereto then party will consult with another will connection with such action unless otherwise mutually determined party nbsp such impasse exists during research term then cellectis will control such action will select counsel such action nbsp such impasse exists following research term then pfizer will control such action will select counsel such action right obligation party under section nbsp expressly subject this section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman infringement third party patent right development manufacture commercialization pfizer licensed product alleged third party infringe third party patent other intellectual property right party becoming aware such allegation will promptly notify other party party that alleged infringe third party patent intellectual property right will have right take such action deems appropriate response such allegation will solely responsible damage cost expense connection therewith subject section style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign confidentiality table style margin margin bottom margin left font size font family time roman confidentiality except extent expressly authorized this agreement party agree that during term each party receiving party receiving confidential information other party disclosing party hereunder will nbsp keep disclosing party confidential information confidential nbsp disclose permit disclosure disclosing party confidential information nbsp permit used disclosing party confidential information purpose provided however that receiving party disclose confidential information disclosing party extent that such confidential information nbsp already known receiving party other than under obligation confidentiality disclosing party time disclosure disclosing party nbsp generally available public otherwise part public domain time disclosure receiving party nbsp became generally available public otherwise part public domain after disclosure receiving party other than through omission receiving party breach obligation under this agreement nbsp disclosed receiving party other than under obligation confidentiality third party obligation disclosing party disclose such information receiving party nbsp independently discovered developed behalf receiving party without confidential information disclosing party style margin margin bottom margin left font size font family time roman authorized disclosure style margin margin bottom margin left font size font family time roman disclosure party representative notwithstanding foregoing provision section nbsp receiving party disclose confidential information belonging disclosing party receiving party affiliate sublicensees officer director employee consultant contractor licensors agent collectively representative nbsp have need know such confidential information connection with performance receiving party obligation exercise receiving party right under this agreement nbsp have agreed writing disclosure provision with respect such confidential information that least restrictive those forth this article style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman disclosure third party style margin margin bottom margin left font size font family time roman notwithstanding foregoing provision section nbsp party disclose confidential information belonging other party style margin margin bottom margin left font size font family time roman governmental authority nbsp extent reasonably necessary obtain maintain inds regulatory approval agreement pfizer licensed product targeting such pfizer target cellectis target cellectis product targeting such cellectis target within territory nbsp order respond inquiry request investigation order subpoena relating this agreement style margin margin bottom margin left font size font family time roman outside consultant contractor advisory board managed care organization clinical clinical investigator each case extent reasonably necessary performance this agreement under reasonable obligation confidentiality style margin margin bottom margin left font size font family time roman extent reasonably necessary connection with filing prosecuting patent right trademark right permitted this agreement style margin margin bottom margin left font size font family time roman extent reasonably necessary connection with prosecuting defending litigation permitted this agreement style margin margin bottom margin left font size font family time roman subject section nbsp connection with included scientific presentation publication relating agreement pfizer licensed product including abstract poster journal article like posting result other information about clinical trial clincialtrials phrma website style margin margin bottom margin left font size font family time roman extent necessary order enforce right under this agreement permitted agreement style margin margin bottom margin left font size font family time roman event party deems reasonably necessary disclose confidential information belonging other party pursuant section nbsp disclosing party will extent possible give reasonable advance written notice such disclosure other party take reasonable measure ensure confidential treatment such information style margin margin bottom margin left font size font family time roman filing other disclosure notwithstanding provision this agreement contrary either party disclose term this agreement extent required reasonable opinion such party legal counsel comply with applicable including rule regulation promulgated united state security exchange commission equivalent governmental agency country territory notwithstanding style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman foregoing before disclosing this agreement term hereof pursuant this section nbsp party will consult with another term this agreement redacted making such disclosure further party discloses this agreement term hereof accordance with this section nbsp such party will expense seek such confidential treatment confidential portion this agreement such other term reasonably requested other party style margin margin bottom margin left font size font family time roman public announcement publication style margin margin bottom margin left font size font family time roman announcement except expressly permitted under section nbsp neither party will make public announcement regarding this agreement without prior written approval other party sake clarity nothing this agreement will prevent nbsp either party from making public disclosure relating this agreement content such public disclosure have previously been made public other than through breach this agreement issuing party affiliate nbsp pfizer from making scientific publication public announcement with respect pfizer licensed product targeting such pfizer target under this agreement provided however that except permitted under section nbsp pfizer will disclose cellectis confidential information such publication announcement without obtaining cellectis prior written consent nbsp cellectis from making scientific publication public announcement with respect cellectis licensed product targeting such cellectis program target under this agreement provided however that except permitted under section nbsp cellectis will disclose pfizer confidential information such publication announcement without obtaining pfizer prior written consent party agree that they will release announcement attached hereto schedule regarding signing this agreement following effective date style margin margin bottom margin left font size font family time roman publication during term each party will submit other party disclosing party review approval proposed academic scientific medical publication public presentation which contains disclosing party confidential information addition each party will submit other party review approval proposed publication public presentation relating research program both instance such review approval will conducted purpose preserving value licensed intellectual property cellectis developed pfizer developed right granted each party hereunder determining whether portion proposed publication presentation containing disclosing party confidential information should modified deleted written copy such proposed publication presentation required submitted hereunder will submitted disclosing party later than thirty nbsp before submission publication presentation review period disclosing party will provide comment with respect such publication presentation within twenty nbsp after receipt such written copy other party will delete confidential information style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman disclosing party upon request review period extended additional sixty nbsp event disclosing party within fifteen nbsp receipt written copy demonstrate reasonable need such extension including preparation filing patent application cellectis pfizer will each comply with standard academic practice regarding authorship scientific publication recognition contribution other party publication governed this section nbsp style margin margin bottom margin left font size font family time roman obligation connection with change control cellectis subject change control cellectis will will cause affiliate representative ensure that confidential information pfizer released nbsp affiliate cellectis that becomes affiliate result change control nbsp representative cellectis relevant surviving entity such change control become representative result change control unless such representative have signed individual confidentiality agreement which include equivalent obligation those this article change control cellectis occurs cellectis will promptly notify pfizer share with pfizer policy procedure plan implement order protect confidentiality pfizer confidential information prior such implementation make adjustment such policy procedure that reasonably requested pfizer style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign representation warranty table style margin margin bottom margin left font size font family time roman mutual representation warranty each cellectis pfizer hereby represents warrant other party that style margin margin bottom margin left font size font family time roman duly organized validly existing good standing under jurisdiction organization style margin margin bottom margin left font size font family time roman execution delivery performance this agreement such party been duly authorized requisite action under provision charter bylaw other organizational document require action approval shareholder other holder voting security voting interest style margin margin bottom margin left font size font family time roman power authority execute deliver this agreement perform obligation hereunder style margin margin bottom margin left font size font family time roman this agreement been duly executed legal valid binding obligation each party enforceable against such party accordance with term style margin margin bottom margin left font size font family time roman execution delivery performance such party this agreement compliance with term provision hereof will conflict with result breach default under binding obligation existing effective date style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman representation warranty cellectis cellectis hereby represents warrant pfizer that style margin margin bottom margin left font size font family time roman except expressly disclosed schedule cellectis sole exclusive owner cellectis technology existing effective date which free clear claim lien charge encumbrance style margin margin bottom margin left font size font family time roman will have full right power authority grant right title interest license other right granted granted pfizer pfizer affiliate under this agreement style margin margin bottom margin left font size font family time roman effective date nbsp schedule forth true complete list cellectis patent right nbsp each such patent right full force effect nbsp cellectis affiliate their licensors have timely paid filing renewal payable with respect such patent right style margin margin bottom margin left font size font family time roman knowledge nbsp cellectis patent right existing effective date upon issuance will valid enforceable patent nbsp effective date except forth schedule third party nbsp infringing cellectis patent right field nbsp challenged threatened challenge extent validity enforceability cellectis patent right including example through institution threat institution interference nullity similar invalidity proceeding before united state patent trademark office analogous foreign governmental authority style margin margin bottom margin left font size font family time roman counsel knowledge have complied with applicable including disclosure requirement connection with filing prosecution maintenance cellectis patent right existing effective date style margin margin bottom margin left font size font family time roman except expressly disclosed schedule cellectis independently developed cellectis know existing effective date otherwise valid right permit pfizer pfizer affiliate pfizer sublicensees such cellectis know permitted purpose under this agreement style margin margin bottom margin left font size font family time roman obtained from inventor cellectis technology existing effective date valid enforceable agreement assigning cellectis each such inventor entire right title interest such cellectis technology style margin margin bottom margin left font size font family time roman except expressly disclosed schedule cellectis technology existing effective date subject funding agreement with governmental authority style margin margin bottom margin left font size font family time roman except expressly disclosed schedule neither cellectis affiliate subject agreement obligation that limit style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman ownership license right granted pfizer affiliate under this agreement including right granted pfizer affiliate access practice grant license sublicenses under provide pfizer sublicensees with access intellectual property right material including patent right know other data information each case that would such agreement obligation included right licensed assigned pfizer affiliate pursuant this agreement style margin margin bottom margin left font size font family time roman nbsp there cellectis third party agreement existing effective date other than cellectis third party agreement expressly disclosed schedule each disclosed third party agreement true complete redacted copy which have been provided pfizer nbsp except provided disclosed third party agreement except servier agreement third party right title interest license under cellectis technology field nbsp right granted cellectis affiliate under disclosed third party agreement conflict with right license granted pfizer affiliate hereunder nbsp cellectis affiliate compliance respect with disclosed third party agreement including diligence obligation cellectis under disclosed third party agreement style margin margin bottom margin left font size font family time roman there nbsp claim demand suit proceeding arbitration inquiry investigation other legal action nature civil criminal regulatory otherwise pending knowledge cellectis threatened against cellectis affiliate nbsp judgment settlement against owed cellectis affiliate each case connection with cellectis technology relating transaction contemplated this agreement style margin margin bottom margin left font size font family time roman representation warranty pfizer pfizer hereby represents warrant cellectis that will have full right power authority grant right title interest license other right granted granted cellectis cellectis affiliate under this agreement style margin margin bottom margin left font size font family time roman cellectis covenant addition covenant made party elsewhere this agreement cellectis hereby covenant other that style margin margin bottom margin left font size font family time roman cellectis will reasonable effort obtain effective date soon thereafter practicable executed confirmatory letter agreement substantially form provided pfizer prior effective date otherwise acceptable pfizer style margin margin bottom margin left font size font family time roman mutual covenant addition covenant made party elsewhere this agreement each party hereby covenant other that from effective date until expiration termination this agreement style margin margin bottom margin left font size font family time roman will nbsp take action that diminishes right under licensed cellectis intellectual property licensed pfizer intellectual property style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman developed granted assigned under this agreement nbsp fail take action that reasonably necessary avoid diminishing right under licensed cellectis intellectual property licensed pfizer intellectual property developed granted assigned pfizer pfizer affiliate under this agreement style margin margin bottom margin left font size font family time roman will nbsp enter into third party agreement that adversely affect nbsp right granted other party hereunder nbsp ability fully perform obligation hereunder nbsp amend terminate otherwise modify third party agreement including cellectis servier agreement consent waive right with respect thereto manner that nbsp adversely affect right granted other party hereunder nbsp ability fully perform obligation hereunder nbsp fulfill cause affiliate fulfill their respective obligation under third party agreement including cellectis servier agreement breach such agreement nbsp inform pfizer existence notice received cellectis affiliate relating alleged breach default cellectis affiliate under third party agreement including servier agreement other notice received cellectis affiliate connection with cellectis third party agreement including disclosed third party agreement that pertain right granted pfizer pfizer affiliate hereunder within after receipt thereof nbsp event that cellectis resolve such alleged breach default notify pfizer within before expiration cure period such breach default under such cellectis third party agreement such that pfizer able cure otherwise resolve such alleged breach default pfizer make payment third party connection with cure other resolution such alleged breach default then pfizer credit amount such payment against royalty other amount payable cellectis pursuant this agreement style margin margin bottom margin left font size font family time roman will enter into otherwise allow itself affiliate subject agreement arrangement which limit ownership right other party affiliate with respect limit ability other party affiliate grant license sublicense access provide provide access other right under intellectual property right material including patent right know other data information each case that would such agreement arrangement included right licensed assigned other party affiliate pursuant this agreement style margin margin bottom margin left font size font family time roman will maintain valid enforceable agreement with person acting behalf itself affiliate under this agreement which require such person assign their entire right title interest patent right know other intellectual property right that conceived generated course performing research plan service style margin margin bottom margin left font size font family time roman representation legal counsel each party hereto represents that been represented legal counsel connection with this agreement acknowledges that style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman participated drafting hereof interpreting applying term provision this agreement party agree that presumption will exist implied against party which drafted such term provision style margin margin bottom margin left font size font family time roman disclaimer foregoing representation warranty each party lieu other representation warranty express implied including implied warranty merchantability implied warranty fitness particular purpose which hereby specifically excluded disclaimed style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign government approval term termination table style margin margin bottom margin left font size font family time roman government approval each cellectis pfizer will cooperate with other party commercially reasonable effort make registration filing application give notice obtain soon practicable governmental other consent transfer approval order qualification authorization permit waiver other thing necessary desirable consummation transaction contemplated hereby style margin margin bottom margin left font size font family time roman term term this agreement term will commence effective date will extend unless this agreement terminated earlier accordance with this article pfizer licensed product pfizer licensed product country country basis until such time royalty term with respect sale such pfizer licensed product such country expires style margin margin bottom margin left font size font family time roman termination pfizer failure cellectis obtain shareholder approval event that cellectis unable obtain approval shareholder august nbsp issuance ordinary share cellectis pfizer pursuant subscription agreement between cellectis pfizer dated effective date then pfizer will have right sole discretion terminate this agreement entirety style margin margin bottom margin left font size font family time roman termination either party cause either party terminate this agreement entirety terminating party option pfizer target pfizer target basis cellectis program target cellectis program target basis applicable time during term this agreement giving written notice other party other party commits material breach obligation under this agreement such breach remains uncured ninety nbsp measured from date written notice such breach given breaching party notwithstanding foregoing party will have right terminate this agreement pursuant this section nbsp nbsp part with respect individual pfizer target cellectis program target applicable only other party material breach giving rise such termination right relates such pfizer target cellectis program target applicable nbsp entirety only such material breach fundamentally frustrates objective transaction contemplated this agreement taken whole affect substantially research program style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman termination pfizer convenience time after nbsp year anniversary effective date pfizer will have right terminate this agreement reason either entirety pfizer target pfizer target basis providing sixty nbsp advance written notice such termination cellectis style margin margin bottom margin left font size font family time roman termination insolvency cellectis this agreement terminated upon written notice pfizer time event cellectis insolvency event style margin margin bottom margin left font size font family time roman effect termination style margin margin bottom margin left font size font family time roman effect termination pfizer failure cellectis obtain shareholder approval pfizer terminates this agreement pursuant section style margin margin bottom margin left font size font family time roman work under research plan will cease style margin margin bottom margin left font size font family time roman right license granted cellectis pfizer pursuant section will terminate style margin margin bottom margin left font size font family time roman right license granted pfizer cellectis pursuant section will terminate style margin margin bottom margin left font size font family time roman pfizer will relieved payment obligation under section nbsp including upfront payment that would become payable pursuant section nbsp style margin margin bottom margin left font size font family time roman material confidential information provided party other party course performance this agreement will returned destroyed directed writing providing party style margin margin bottom margin left font size font family time roman effect termination pfizer cause pfizer terminates this agreement with respect pfizer target pursuant section nbsp each terminated target style margin margin bottom margin left font size font family time roman work under applicable research plan with respect each terminated target will cease style margin margin bottom margin left font size font family time roman license granted pfizer with respect such terminated target pfizer licensed product targeting such terminated target each terminated pfizer licensed product including under section nbsp will continue become irrevocable perpetual pfizer will have further obligation cellectis under this agreement with respect such terminated target terminated pfizer licensed product including further obligation milestone payment other than nbsp those obligation that expressly survive termination accordance with section nbsp nbsp obligation royalty style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman with respect sale terminated pfizer licensed product accordance with term condition this agreement amount equal amount that would otherwise have been payable under this agreement style margin margin bottom margin left font size font family time roman pfizer terminates this agreement entirety pursuant section nbsp pfizer terminates this agreement entirety pursuant section nbsp nbsp license granted pfizer cellectis under section will terminate nbsp pfizer will have further obligation cellectis under this agreement other than those obligation that expressly survive termination accordance with section nbsp nbsp material confidential information provided pfizer cellectis course performance this agreement will returned destroyed directed writing pfizer style margin margin bottom margin left font size font family time roman pfizer will have right offset against payment owing cellectis under subparagraph nbsp above damage found agreed party owed cellectis pfizer style margin margin bottom margin left font size font family time roman cellectis will remain entitled receive payment that accrued before effective date such termination style margin margin bottom margin left font size font family time roman nothing this section nbsp will limit other remedy pfizer have cellectis breach this agreement style margin margin bottom margin left font size font family time roman right obligation party with respect pfizer target other than such terminated target will remain full force effect style margin margin bottom margin left font size font family time roman effect termination pfizer insolvency cellectis pfizer terminates this agreement pursuant section style margin margin bottom margin left font size font family time roman cellectis will have further obligation perform obligation under this agreement including cellectis obligation under research program other than those obligation that expressly survive termination this agreement accordance with section style margin margin bottom margin left font size font family time roman license granted pfizer including under section nbsp will continue become subject only royalty obligation forth below this section nbsp irrevocable perpetual pfizer will have further obligation cellectis under this agreement including further obligation milestone payment other than nbsp those obligation that expressly survive termination accordance with section nbsp nbsp obligation royalty with respect sale pfizer licensed product accordance with term condition this agreement style margin margin bottom margin left font size font family time roman cellectis will remain entitled receive payment that accrued before effective date such termination style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman pfizer will have right offset against payment owing cellectis under subparagraph nbsp above damage found agreed party owed cellectis pfizer style margin margin bottom margin left font size font family time roman nothing this section nbsp will limit other remedy pfizer have cellectis breach this agreement style margin margin bottom margin left font size font family time roman effect termination cellectis cause pfizer convenience style margin margin bottom margin left font size font family time roman cellectis terminates this agreement with respect pfizer target pursuant section nbsp pfizer terminates this agreement with respect pfizer target pursuant section nbsp then nbsp license granted cellectis pfizer under section with respect such pfizer target nbsp pfizer licensed product targeting such pfizer target will terminate nbsp material confidential information provided cellectis pfizer course performance this agreement will returned destroyed directed writing cellectis style margin margin bottom margin left font size font family time roman cellectis terminates this agreement entirety pursuant section nbsp pfizer terminates this agreement entirety pursuant section nbsp nbsp license granted cellectis pfizer under section will terminate nbsp cellectis will have further obligation pfizer under this agreement other than those obligation that expressly survive termination accordance with section nbsp nbsp right license granted pfizer cellectis pursuant section nbsp will continue nbsp pfizer right first refusal forth section nbsp will continue extent that such cellectis product covered licensed pfizer intellectual property nbsp material confidential information provided cellectis pfizer course performance this agreement will returned destroyed directed writing cellectis style margin margin bottom margin left font size font family time roman event that cellectis terminates this agreement cause pursuant section nbsp pfizer terminates this agreement without cause pursuant section nbsp with respect licensed pfizer product targeting pfizer target cellectis written notice pfizer which notice only delivered within following effective date such termination unless such termination related material concern regarding safety compound product party will negotiate good faith period exceed following effective date termination regarding style margin margin bottom margin left font size font family time roman grant pfizer cellectis royalty bearing exclusive license under applicable pfizer technology permitting cellectis continue develop commercialize manufacture product under development commercialization pfizer under this agreement time termination form which such product then exists continuation product style margin margin bottom margin left font size font family time roman related transfer cellectis development data regulatory filing specifically relating such continuation product granting cellectis right reference with respect such data filing style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman neither party will obligated enter into transaction described section nbsp neither party will have liability other failure style margin margin bottom margin left font size font family time roman avoidance doubt cellectis terminates this agreement with respect pfizer target pursuant section nbsp pfizer terminates this agreement with respect pfizer target pursuant section nbsp each case including pfizer target event that this agreement terminated entirety such pfizer target will longer considered pfizer target purpose this agreement style margin margin bottom margin left font size font family time roman satisfaction obligation during notice period during period from providing notice termination through termination agreement party will continue perform their obligation under this agreement style margin margin bottom margin left font size font family time roman pending dispute resolution party give notice termination under section nbsp other party dispute whether such notice proper then issue whether this agreement been terminated will resolved accordance with section nbsp this agreement will remain effect pending resolution such dispute result such dispute resolution process determined that notice termination proper then such termination will effective immediately result such dispute resolution process determined that notice termination improper then termination will have occurred this agreement will remain effect style margin margin bottom margin left font size font family time roman disposition inventory product following termination this agreement with respect more pfizer target pfizer affiliate sublicensees will have right continue sell their existing inventory pfizer licensed product targeting such pfizer target that have received regulatory approval prior such termination period exceed after effective date such termination expiration pfizer will royalty payable connection with such sale accordance with section style margin margin bottom margin left font size font family time roman survival certain obligation expiration termination this agreement will relieve party obligation that accrued before such expiration termination following provision will survive expiration termination this agreement section definition report payment maintenance audit right confidentiality representation warranty effect termination limitation liability miscellaneous addition section that referred above listed section shall survive solely interpretation enforcement listed section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman right termination research project research program pfizer upon change control cellectis change control cellectis consummated during research term pfizer will have right terminate research project research program entirety upon written notice cellectis within after consummation such change control cellectis such termination research project research program nbsp will constitute termination this agreement nbsp will affect party right obligation under this agreement other than those relating such research project research program nbsp will relieve either party obligation that arose prior such termination following such termination research project research program applicable pfizer will have further funding obligation under article section nbsp with respect such research project research program applicable other than that which have accrued prior such termination addition time following change control cellectis consummated during research term cellectis successor fails perform obligation under research program material respect then effective upon written notice cellectis successor pfizer will have right terminate research project research program entirety pursuant this section nbsp cellectis will promptly transfer pfizer additional cost pfizer such cellectis know cellectis improvement including related material necessary pfizer complete activity contemplated under such research project research program applicable avoidance doubt event that pfizer terminates research project research program accordance with this section nbsp such termination will deemed termination cause under section nbsp termination convenience under section nbsp only effect such termination forth this section nbsp notwithstanding provision this agreement contrary nothing this section nbsp will limit preclude pfizer from seeking other remedy pfizer have cellectis breach this agreement provided that pfizer seek remedy under both this section nbsp section nbsp with respect same performance failure cellectis successor style margin margin bottom margin left font size font family time roman bankruptcy right license granted under pursuant this agreement cellectis will otherwise deemed purpose section nbsp bankruptcy code license right intellectual property defined under section nbsp bankruptcy code party agree that pfizer licensee intellectual property under this agreement will retain fully exercise right election under bankruptcy code party further agree that event rejection this agreement cellectis bankruptcy proceeding against cellectis under bankruptcy code nbsp pfizer will entitled complete duplicate complete access appropriate such intellectual property embodiment such intellectual property which already pfizer possession will promptly delivered upon pfizer written request therefor nbsp cellectis will interfere with pfizer right intellectual property embodiment intellectual property will assist interfere with pfizer obtaining intellectual style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman property embodiment intellectual property from another entity term embodiment intellectual property includes tangible intangible electronic other embodiment right license hereunder including compound product embodying intellectual property pfizer licensed product filing with regulatory authority related right cellectis technology style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign limitation liability indemnification insurance table style margin margin bottom margin left font size font family time roman consequential damage except with respect liability arising from breach article from willful misconduct intentionally wrongful extent such party required provide indemnification under this article event will either party affiliate sublicensees affiliate sublicensees respective representative liable under this agreement special indirect incidental consequential punitive damage whether contract warranty tort negligence strict liability otherwise including loss profit revenue suffered either party respective affiliate representative without limiting generality foregoing consequential damage will deemed include neither party will liable other party such other party affiliate representative stockholder damage based measured loss projected speculative future sale pfizer licensed product milestone payment upon unachieved event under section nbsp unearned royalty under section nbsp other unearned speculative otherwise contingent payment provided this agreement style margin margin bottom margin left font size font family time roman indemnification pfizer pfizer will indemnify defend hold harmless cellectis affiliate their sublicensees contractor subcontractor distributor each their respective employee officer director agent each cellectis indemnified party from against liability loss damage expense including reasonable attorney expense cost collectively liability that cellectis indemnified party required more third party resulting from arising style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman indemnification cellectis cellectis will indemnify defend hold harmless pfizer affiliate sublicensees contractor distributor each their respective employee officer director agent each pfizer indemnified party from against liability that pfizer indemnified party required more third party resulting from arising style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman procedure style margin margin bottom margin left font size font family time roman notice each party will notify other party writing event becomes aware claim which indemnification sought hereunder event that third party asserts claim other proceeding including governmental investigation with respect matter which party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman indemnified party entitled indemnification hereunder third party claim then indemnified party will promptly notify party obligated indemnify indemnified party indemnifying party thereof provided however that delay part indemnified party notifying indemnifying party will relieve indemnifying party from obligation hereunder unless then only extent that indemnifying party prejudiced thereby style margin margin bottom margin left font size font family time roman control subject pfizer right control action described section nbsp even where cellectis indemnifying party indemnifying party will have right exercisable notice indemnified party within nbsp business after receipt notice from indemnified party commencement assertion third party claim assume direction control defense litigation settlement appeal other disposition third party claim including right settle claim solely monetary consideration with counsel selected indemnifying party reasonably acceptable indemnified party provided that nbsp indemnifying party sufficient financial resource reasonable judgment indemnified party satisfy amount adverse monetary judgment that sought nbsp third party claim seek solely monetary damage nbsp indemnifying party expressly agrees writing that between indemnifying party indemnified party indemnifying party will solely obligated satisfy discharge third party claim full condition forth clause nbsp nbsp above collectively referred litigation condition within nbsp business after indemnifying party given notice indemnified party exercise right defend third party claim indemnified party will give notice indemnifying party objection thereto based upon litigation condition indemnified party reasonably object indemnified party will continue defend third party claim expense indemnifying party until such time such objection withdrawn such notice given such objection withdrawn indemnifying party will entitled sole cost expense assume direction control such defense with counsel selected indemnifying party reasonably acceptable indemnified party during such time indemnifying party controlling defense such third party claim indemnified party will cooperate will cause affiliate agent cooperate upon request indemnifying party defense prosecution third party claim including furnishing such record information testimony attending such conference discovery proceeding hearing trial appeal reasonably requested indemnifying party event that indemnifying party satisfy litigation condition notify indemnified party indemnifying party intent defend third party claim within nbsp business after notice thereof indemnified party without further notice indemnifying party undertake defense thereof with counsel choice indemnifying party expense including reasonable pocket attorney cost expense enforcement defense indemnifying party indemnified style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman party case will have right join including right conduct discovery interview examine witness participate settlement conference control expense defense third party claim that other party defending provided this agreement style margin margin bottom margin left font size font family time roman settlement indemnifying party will without prior written consent indemnified party enter into compromise settlement that commits indemnified party take forbear take action indemnified party will have sole exclusive right settle third party claim such term condition deems reasonably appropriate extent such third party claim involves equitable other monetary relief will have right settle such third party claim extent such third party claim involves monetary damage without prior written consent indemnifying party each indemnifying party indemnified party will make admission liability respect third party claim without prior written consent other party indemnified party will reasonable effort mitigate liability arising from such third party claim style margin margin bottom margin left font size font family time roman insurance each party will obtain maintain during term commercial general liability insurance including product liability insurance with reputable financially secure insurance carrier pursuant program self insurance reasonably satisfactory other party cover indemnification obligation under section nbsp section nbsp applicable each case with limit than occurrence aggregate style font size margin margin bottom nbsp table style border collapse collapse font family time roman font size border cellpadding cellspacing width width valign align left align left valign miscellaneous table style margin margin bottom margin left font size font family time roman other cellectis target sake clarity except forth section nbsp exclusivity selection other cellectis target target selection process right negotiation other cellectis target outside scope this agreement style margin margin bottom margin left font size font family time roman assignment either party assign this agreement interest hereunder without prior written consent other which consent will unreasonably withheld delayed except that this agreement assigned follows nbsp party assign right obligation under this agreement sale itself sale portion business which this agreement relates through merger sale asset sale stock ownership interest nbsp party assign right obligation under this agreement affiliate this agreement will binding upon successor permitted assigns party name party appearing herein will deemed include name such party successor permitted assigns extent necessary carry intent this agreement assignment accordance with this section nbsp will void style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman further action each party agrees execute acknowledge deliver such further instrument such other necessary appropriate order carry purpose intent agreement style margin margin bottom margin left font size font family time roman force majeure each party will excused from performance obligation under this agreement extent that such performance prevented force majeure defined below nonperforming party promptly provides notice prevention other party such excuse will continued long condition constituting force majeure continues nonperforming party take commercially reasonable effort resume performance purpose this agreement force majeure will include condition beyond control party including voluntary involuntary compliance with applicable order government terror civil commotion labor strike lock epidemic failure default public utility common carrier destruction production facility material fire earthquake storm like catastrophe style margin margin bottom margin left font size font family time roman notice notice notification required permitted provided pursuant term condition this agreement including notice force majeure breach termination change address will writing will deemed given upon receipt delivered personally facsimile transmission receipt verified five after deposited mail mailed registered certified mail return receipt requested postage prepaid next business sent overnight delivery using nationally recognized express courier service specifying next business delivery receipt verified party following address facsimile number such other address facsimile number party will specified like notice provided however that notice change address will effective only upon receipt thereof style margin margin bottom margin left font size font family time roman correspondence pfizer will addressed follows style margin margin bottom margin left font size font family time roman pfizer style margin margin bottom margin left font size font family time roman notice business development style margin margin bottom margin left font size font family time roman east street style margin margin bottom margin left font size font family time roman york style margin margin bottom margin left font size font family time roman attention contract notice style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman with copy style margin margin bottom margin left font size font family time roman pfizer style margin margin bottom margin left font size font family time roman notice pfizer legal division style margin margin bottom margin left font size font family time roman east street style margin margin bottom margin left font size font family time roman york style margin margin bottom margin left font size font family time roman attn chief counsel style margin margin bottom margin left font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman correspondence cellectis will addressed follows style margin margin bottom margin left font size font family time roman cellectis style margin margin bottom margin left font size font family time roman croix jarry style margin margin bottom margin left font size font family time roman paris style margin margin bottom margin left font size font family time roman attn chief executive officer style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman with copy style margin margin bottom margin left font size font family time roman cellectis style margin margin bottom margin left font size font family time roman croix jarry style margin margin bottom margin left font size font family time roman paris style margin margin bottom margin left font size font family time roman attn general counsel style margin margin bottom margin left font size font family time roman style margin margin bottom margin left font size font family time roman amendment amendment modification supplement provision this agreement will valid effective unless made writing signed duly authorized officer each party style margin margin bottom margin left font size font family time roman waiver provision this agreement will waived omission knowledge party agent employee except instrument writing expressly waiving such provision signed duly authorized officer waiving party waiver either party breach provision hereof other party will construed waiver succeeding breach such provision waiver provision itself style margin margin bottom margin left font size font family time roman severability clause portion thereof this agreement reason held invalid illegal unenforceable same will affect other portion this agreement intent party that this agreement will construed such fashion maintain existence validity enforceability greatest extent possible such event this agreement will construed such clause portion thereof never been contained this agreement there will deemed substituted therefor such provision will most nearly carry intent party expressed this agreement fullest extent permitted applicable style margin margin bottom margin left font size font family time roman descriptive heading descriptive heading this agreement convenience only will force effect construing interpreting provision this agreement style margin margin bottom margin left font size font family time roman dispute resolution dispute disagreement arises between pfizer cellectis respect this agreement they will follow following procedure attempt resolve dispute disagreement style margin margin bottom margin left font size font family time roman party claiming that such dispute exists will give notice writing notice dispute other party nature dispute style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman within receipt notice dispute pfizer alliance manager cellectis alliance manager will meet person teleconference exchange written summary reflecting reasonable detail nature extent dispute this meeting they will their reasonable endeavor resolve dispute style margin margin bottom margin left font size font family time roman alliance manager unable resolve dispute during meeting described section nbsp reason such meeting take place within period specified section nbsp then dispute will referred which will meet later following initial receipt notice dispute reasonable endeavor resolve dispute style margin margin bottom margin left font size font family time roman unable resolve dispute during meeting described section nbsp reason such meeting take place within period specified section nbsp then head rinat chief executive office cellectis will meet mutually agreed upon time location purpose resolving such dispute style margin margin bottom margin left font size font family time roman within further period event within initial receipt notice dispute dispute been resolved reason meeting described section nbsp been held within initial receipt notice dispute then party agree that subject section nbsp below either party initiate litigation resolve dispute style margin margin bottom margin left font size font family time roman election resolution process notwithstanding provision section nbsp contrary nbsp either party raise allegation claim misuse each misuse allegation nbsp party unable resolve such misuse allegation pursuant dispute escalation process described section through escalation process then following completion escalation process party mutually agree have such misuse allegation resolved pursuant term section nbsp arbitration process party fail agree arbitration pursuant section nbsp timely manner exceed then party will deemed have elected have such misuse allegation resolved through litigation style margin margin bottom margin left font size font family time roman arbitration process party mutually elect resolve misuse allegation pursuant arbitration process then such misuse allegation will referred finally resolved binding arbitration accordance with commercial rule procedure rule international chamber commerce arbitral tribunal composed three arbitrator whom will have relevant experience pharmaceutical industry appointed agreement party accordance with rule time arbitration party agree writing submit dispute single arbitrator said single arbitrator will nbsp have relevant experience pharmaceutical industry nbsp appointed agreement party failing such agreement accordance with rule foregoing style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman arbitration proceeding commenced either party written notice other party unless otherwise agreed party hereto such arbitration proceeding will held london england provided that proceeding conducted telephone conference call with consent both party arbitrator arbitration proceeding will conducted english language style margin margin bottom margin left font size font family time roman limited discovery documentary discovery conducted discretion arbitrator provided that such discovery will nbsp limited document directly relating misuse allegation nbsp conducted pursuant document discovery procedure forth under state york nbsp conducted subject schedule stipulated party absence stipulation schedule ordered arbitrator nbsp require either party affiliate their respective employee officer director agent subject deposition notwithstanding provision this section nbsp contrary discovery must completed within sixty nbsp notice commencement arbitration proceeding style margin margin bottom margin left font size font family time roman award arbitrator only consider award direct monetary damage will under circumstance have authority grant nbsp injunctive relief nbsp equitable relief nbsp order specific performance nbsp punitive damage nbsp consequential damage described section nbsp allocation expense arbitration including reasonable attorney will determined arbitrator absence such determination each party will expense style margin margin bottom margin left font size font family time roman ruling arbitration proceeding must completed within notice commencement arbitration proceeding party hereby agree that subject provision this section nbsp arbitrator authority issue ruling order regarding procedural evidentiary matter that arbitrator deem reasonable necessary with without petition therefore party well final ruling judgment ruling will issued written order summarizing arbitration proceeding more than after final submission party ruling arbitrator will final appealable court except circumstance where such ruling comply with term section style margin margin bottom margin left font size font family time roman enforcement ruling court competent jurisdiction ruling issued arbitrator pursuant section nbsp enforced extent that such ruling complies with provision section nbsp court having jurisdiction over party their respective asset style margin margin bottom margin left font size font family time roman confidentiality activity undertaken arbitrator party pursuant this section nbsp will conducted subject obligation confidentiality restrictive than those forth section nbsp further party acknowledge agree that their respective conduct during course arbitration their respective statement information exchanged connection with arbitration confidential information under this agreement subject provision section style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman unauthorized disclosure confidential information third party notwithstanding provision this agreement contrary nbsp provision this section nbsp will apply pfizer disclosure cellectis confidential information third party violation section nbsp nbsp cellectis reserve right under section nbsp immediately initiate litigation seeking remedy equity including issuance preliminary temporary permanent injunction preserve enforce right under section nbsp with respect such unauthorized disclosure style margin margin bottom margin left font size font family time roman governing this agreement claim arising under connection therewith will governed interpreted accordance with substantive state york without regard conflict principle thereof style margin margin bottom margin left font size font family time roman consent jurisdiction each party this agreement execution hereof nbsp hereby irrevocably submits exclusive jurisdiction united kingdom purpose action suit proceeding arising whole part related based upon connection with this agreement subject matter hereof hereby waif extent prohibited applicable agrees assert motion defense otherwise such action claim that subject personally jurisdiction above named court that property exempt immune from attachment execution that such action brought above named court should dismissed ground forum conveniens should transferred court other than above named court should stayed reason pendency some other proceeding other court other than above named court that this agreement subject matter hereof enforced such court nbsp hereby agrees commence such action other than before above named court make motion take other action seeking intending cause transfer removal such action court other than above named court whether ground inconvenient forum otherwise style margin margin bottom margin left font size font family time roman entire agreement this agreement including exhibit schedule constitutes contains complete final exclusive understanding agreement party cancel supersedes prior negotiation correspondence understanding agreement whether oral written between party respecting subject matter hereof thereof including confidentiality agreement which hereby terminated effective effective date provided that such confidentiality agreement will continue govern treatment confidential information disclosed party prior effective date accordance with term style margin margin bottom margin left font size font family time roman independent contractor both party independent contractor under this agreement nothing herein contained will deemed create employment agency joint venture partnership relationship between party hereto their agent employee other legal arrangement that would impose liability upon party style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom margin left font size font family time roman failure other party neither party will have express implied power enter into contract commitment incur liability name behalf other party bind other party respect whatsoever style margin margin bottom margin left font size font family time roman pfizer anti bribery anti corruption practice throughout term this agreement cellectis affiliate subcontractor must comply with anti bribery anti corruption provision forth attachment hereto style margin margin bottom margin left font size font family time roman counterpart this agreement executed counterpart each which will original both which will constitute together same document counterpart signed delivered facsimile file each which will binding when received applicable party style margin margin bottom margin left font size font family time roman third party right obligation provision this agreement will deemed construed result creation right obligation person party this agreement however pfizer decide sole discretion more affiliate perform obligation duty hereunder provided that pfizer will remain liable hereunder performance such affiliate such obligation style margin margin bottom text indent font size font family time roman witness whereof duly authorized representative party have duly executed this agreement effective effective date style font size margin margin bottom nbsp table cellspacing cellpadding width border style border collapse collapse font family time roman font size width valign bottom width width valign bottom width width valign bottom width valign bottom width width style font family time roman font size valign colspan pfizer valign bottom valign valign bottom valign colspan cellectis style font size height height colspan height colspan height colspan height colspan style font family time roman font size valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman valign bottom valign valign bottom valign valign bottom valign style margin margin bottom border bottom solid font size font family time roman style font family time roman font size valign name valign bottom valign dolsten valign bottom valign valign bottom valign name valign bottom valign andr eacute choulika style font family time roman font size valign title valign bottom valign president valign bottom valign valign bottom valign title valign bottom valign table style margin margin bottom font size nbsp style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center attachment style margin margin bottom font size font family time roman align center pfizer anti bribery anti corruption practice style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman align center exhibit attachment style margin margin bottom font size font family time roman align center pfizer anti bribery anti corruption principle style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule expected subcontractor style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule research plan style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman appendix style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman appendix style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman appendix style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman appendix style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule licensed patent right comprised cellectis technology style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule cellectis patent right style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule exception representation warranty cellectis style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule exception representation warranty cellectis style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule exception representation warranty cellectis style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center style page break before always size style color width align center style margin margin bottom font size font family time roman schedule disclosed third party agreement style margin margin bottom font size font family time roman style margin margin bottom font size nbsp style margin margin bottom font size font family time roman confidential material redacted separately filed with commission style margin margin bottom font size font family time roman align center body html text document